JPH0359899B2 - - Google Patents

Info

Publication number
JPH0359899B2
JPH0359899B2 JP59175117A JP17511784A JPH0359899B2 JP H0359899 B2 JPH0359899 B2 JP H0359899B2 JP 59175117 A JP59175117 A JP 59175117A JP 17511784 A JP17511784 A JP 17511784A JP H0359899 B2 JPH0359899 B2 JP H0359899B2
Authority
JP
Japan
Prior art keywords
group
tad
reduced pressure
mmol
under reduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59175117A
Other languages
Japanese (ja)
Other versions
JPS6153257A (en
Inventor
Masao Yoshida
Tsugio Tomyoshi
Masao Takei
Tetsuyuki Saino
Rinzo Nishizawa
Teruya Nakamura
Hamao Umezawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takara Shuzo Co Ltd
Nippon Kayaku Co Ltd
Original Assignee
Takara Shuzo Co Ltd
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Shuzo Co Ltd, Nippon Kayaku Co Ltd filed Critical Takara Shuzo Co Ltd
Priority to JP59175117A priority Critical patent/JPS6153257A/en
Publication of JPS6153257A publication Critical patent/JPS6153257A/en
Publication of JPH0359899B2 publication Critical patent/JPH0359899B2/ja
Granted legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

【発明の詳細な説明】 〔産業上の利用分野〕 本発明は抗腫瘍作用等を有する物質の新規製造
法に関するものである。
DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a new method for producing a substance having antitumor activity.

〔従来の技術〕[Conventional technology]

スパガリン(Spargualin)は、微生物の培養
液より単離された抗腫瘍作用を有する物質であり
(T.Takeuchi,et al.,J.Antibiotics,34,1619
(1981)参照)、下記の構造を有するが、ヘミアセ
タール構造を有するため水溶液中で極めて不安定
である。
Spargualin is a substance with antitumor activity isolated from the culture solution of microorganisms (T. Takeuchi, et al., J. Antibiotics, 34, 1619).
(1981)) and has the following structure, but it is extremely unstable in aqueous solution because it has a hemiacetal structure.

その後スパガリン関連化合物について種々の研
究が行われ、特開昭59−42356号には水溶液中で
安定なスパガリン化合物が開示され、10−アミノ
アシル−1,5−ジ保護−1,5,10−トリアザ
デカンとω−グアニジノ脂肪酸を縮合させた後、
保護基を脱離することにより目的化合物を得てい
る。
After that, various studies were conducted on spagarin-related compounds, and JP-A-59-42356 disclosed a spagarin compound that is stable in aqueous solution, and 10-aminoacyl-1,5-diprotected-1,5,10-triazadecane. After condensing and ω-guanidino fatty acid,
The target compound is obtained by removing the protecting group.

〔発明が解決しようとする問題点〕[Problem that the invention seeks to solve]

工業的規模の製造に適する合成法を見い出すこ
と。
To find synthetic methods suitable for industrial scale production.

〔問題点を解決するための手段〕[Means for solving problems]

本発明者らは、スパガリン関連化合物の大量合
成に適した製造法を鋭意検討した結果、下記一般
式〔〕の化合物をグアニジノ化し、保護基を脱
離することにより、下記一般式〔〕の化合物を
収率よく合成できることを発見し本発明を完成す
るに到つた。
As a result of extensive research into a manufacturing method suitable for large-scale synthesis of spagarin-related compounds, the present inventors have determined that the compound of the following general formula [] can be synthesized by guanidinating the compound of the following general formula [] and removing the protective group. The present invention was completed by discovering that it is possible to synthesize with good yield.

即ち、本発明は、一般式 〔式中R′1はグリシンあるいはセリンのアミノ
基から水素原子1個およびカルボキシル基からヒ
ドロキシル基を除いた残基(セリン残基における
ヒドロキシル基は保護されていてもよい。)を示
し、隣接するカルボニル基およびアミノ基と酸ア
ミド結合しており、R2はアミノ基の保護基を示
し、mは3から5の整数である。〕 で表わされる10−〔N−(ω−(4−アミノフエニ
ル)アシル)アミノアシル〕−1,5−ジ保護−
1,5,10−トリアザデカンをグアニジノ化し、
次いで保護基を脱離することを特徴とする、一般
〔式中R1はグリシンあるいはセリンのアミノ
基から水素原子1個およびカルボキシル基からヒ
ドロキシル基を除いた残基、mは前記に同じであ
る。〕 で表わされる10−〔N−(ω−(4−グアニジノフ
エニル)アシル)アミノアシル〕−1,5,10−
トリアザデカンまたはその塩の製造法ならびに一
般式〔〕で表わされる1,5,10−トリアザデ
カン誘導体に関するものである。
That is, the present invention provides the general formula [In the formula, R′ 1 represents a residue obtained by removing one hydrogen atom from the amino group of glycine or serine and the hydroxyl group from the carboxyl group (the hydroxyl group in the serine residue may be protected), and the adjacent It has an acid amide bond with a carbonyl group and an amino group, R 2 represents a protecting group for the amino group, and m is an integer from 3 to 5. ] 10-[N-(ω-(4-aminophenyl)acyl)aminoacyl]-1,5-diprotected-
Guanidination of 1,5,10-triazadecane,
The general formula is characterized in that the protecting group is then removed. [In the formula, R 1 is a residue obtained by removing one hydrogen atom from the amino group of glycine or serine and the hydroxyl group from the carboxyl group, and m is the same as above. ] 10-[N-(ω-(4-guanidinophenyl)acyl)aminoacyl]-1,5,10-
The present invention relates to a method for producing triazadecane or a salt thereof, and a 1,5,10-triazadecane derivative represented by the general formula [].

一般式〔〕で表わされる10−〔N−(ω−(4
−アミノフエニル)アシル)アミノアシル)〕−
1,5−ジ保護−1,5,10−トリアザデカンの
グアニジノ化はO−メチルイソウレア等のO−低
級アルキルイソウレア、S−メチルチオウレア等
のS−低級アルキルチオウレア、1−グアニル−
3,5−ジメチルピラゾール等の1−グアニルピ
ラゾール誘導体、あるいはシアナミド等の公知の
グアニジノ化試薬により公知の方法で行うことが
できる。例えば、O−メチルイソウレアあるいは
S−メチルチオウレアを用いる場合は一般式
〔〕で表わされる10−〔N−(ω−(4−アミノフ
エニル)アシル)アミノアシル〕−1,5−ジ保
護−1,5,10−トリアザデカンを溶媒に溶解
し、グアニジノ化試薬を添加後塩基例えば水酸化
ナトリウム等の強塩基の水溶液を加えPHを中性〜
アルカリ性好ましくは9〜11に調整し0℃以上好
ましくは室温から溶媒の沸点の温度で反応が終了
するまで、例えば5ないし48時間反応させること
により行えばよい。使用する溶剤としては水と均
一に混合する有機溶剤ならば特に制限はないが、
メタノール、エタノール、プロパノール等の低級
アルコール、ジオキサン、テトラヒドロフラン等
のエーテル類、アセトン等のケトン類、ジメチル
ホルムアミド等のアミド類、アセトニトリル等の
ニトリル類が好ましい。1−グアニル−3,5−
ジメチルピラゾールを用いる場合は前記O−メチ
ルイソウレアおよびS−メチルチオウレアと同様
に行えるが、その他非水系でも行うことができ
る。すなわち、溶媒としては反応に関与しない有
機溶剤なら特に制限はないが、メタノール、エタ
ノール、プロパノール等の低級アルコール、ジメ
チルエーテル、ジオキサン、テトラヒドロフラン
等のエーテル類、酢酸エチル等のエステル類、ア
セトン等のケトン類、クロロホルム、塩化メチレ
ン等のハロゲン化炭化水素類、ジメチルホルムア
ミド等のアミド類、アセトニトリル等のニトリル
類等が望ましく、塩基としてはトリエチルアミ
ン、ジイソプロピルエチルアミン等の有機塩基を
用いれば良い。反応温度は0℃以上好ましくは室
温から溶媒の沸点の温度範囲である。反応時間は
特に制限はなく、反応が完結するまで行えばよ
く、通常5ないし24時間撹拌反応させることによ
り完結する。
10-[N-(ω-(4
-aminophenyl)acyl)aminoacyl)]-
Guanidination of 1,5-diprotected-1,5,10-triazadecane can be performed using O-lower alkyl isourea such as O-methylisourea, S-lower alkylthiourea such as S-methylthiourea, or 1-guanyl-
This can be carried out by a known method using a 1-guanylpyrazole derivative such as 3,5-dimethylpyrazole, or a known guanidination reagent such as cyanamide. For example, when using O-methylisourea or S-methylthiourea, 10-[N-(ω-(4-aminophenyl)acyl)aminoacyl]-1,5-diprotected-1, Dissolve 5,10-triazadecane in a solvent, add a guanidination reagent, and then add a base such as an aqueous solution of a strong base such as sodium hydroxide to bring the pH to neutral.
The alkalinity is preferably adjusted to 9 to 11, and the reaction is carried out at a temperature of 0 DEG C. or higher, preferably from room temperature to the boiling point of the solvent, until the reaction is completed, for example, for 5 to 48 hours. There are no particular restrictions on the solvent used, as long as it is an organic solvent that mixes uniformly with water.
Preferred are lower alcohols such as methanol, ethanol and propanol, ethers such as dioxane and tetrahydrofuran, ketones such as acetone, amides such as dimethylformamide, and nitriles such as acetonitrile. 1-guanyl-3,5-
When dimethylpyrazole is used, it can be carried out in the same manner as the above-mentioned O-methylisourea and S-methylthiourea, but other non-aqueous systems can also be used. In other words, the solvent is not particularly limited as long as it is an organic solvent that does not participate in the reaction, but lower alcohols such as methanol, ethanol, and propanol, ethers such as dimethyl ether, dioxane, and tetrahydrofuran, esters such as ethyl acetate, and ketones such as acetone can be used as the solvent. , halogenated hydrocarbons such as chloroform and methylene chloride, amides such as dimethylformamide, and nitriles such as acetonitrile, etc., and organic bases such as triethylamine and diisopropylethylamine may be used as the base. The reaction temperature is 0° C. or higher, preferably in the temperature range from room temperature to the boiling point of the solvent. The reaction time is not particularly limited and may be carried out until the reaction is completed, which is usually completed by stirring the reaction for 5 to 24 hours.

シアナミドを用いる場合は、一般式〔〕で表
わされる10−〔N−(ω−(4−アミノフエニル)
アシル)アミノアシル〕−1,5−ジ保護−1,
5,10−トリアザデカンの塩酸、臭化水素酸、硝
酸あるいは硫酸等の鉱酸との塩またはギ酸、酢
酸、プロピオン酸等の有機酸との塩を溶媒に溶解
し、シアナミドを添加し0℃以上好ましくは室温
から溶媒の沸点の温度で反応させる。反応は通常
1時間から12時間で定常に達する。原料が残つて
いる場合は酸を添加し好ましくはPHを3〜5に調
整することにより反応を加速できる。使用する溶
媒は特に制限はないが、水あるいは水と均一に混
合する有機溶剤の含水溶媒さらには有機溶媒のみ
の非水系でも行える。有機溶剤としてはメタノー
ル、エタノール、プロパノール、n−ブタノール
等のアルコール類、ジオキサン、テトラヒドロフ
ラン等のエーテル類、酢酸エチル等のエステル
類、アセトン等のケトン類、ジメチルホルムアミ
ド等のアミド類、アセトニトリル等のニトリル類
が好ましい。
When cyanamide is used, 10-[N-(ω-(4-aminophenyl)
acyl)aminoacyl]-1,5-diprotected-1,
A salt of 5,10-triazadecane with a mineral acid such as hydrochloric acid, hydrobromic acid, nitric acid, or sulfuric acid, or a salt with an organic acid such as formic acid, acetic acid, or propionic acid is dissolved in a solvent, cyanamide is added, and the temperature is heated above 0°C. The reaction is preferably carried out at a temperature ranging from room temperature to the boiling point of the solvent. The reaction usually reaches steady state in 1 to 12 hours. If raw materials remain, the reaction can be accelerated by adding an acid and preferably adjusting the pH to 3 to 5. The solvent to be used is not particularly limited, but water or a water-containing solvent such as an organic solvent that mixes uniformly with water, or a non-aqueous solvent containing only an organic solvent may be used. Examples of organic solvents include alcohols such as methanol, ethanol, propanol, and n-butanol, ethers such as dioxane and tetrahydrofuran, esters such as ethyl acetate, ketones such as acetone, amides such as dimethylformamide, and nitriles such as acetonitrile. Preferably.

グアニジノ化試薬の使用量は一般式〔〕の化
合物に対し、0.5モル以上好ましくは1モル以上
使用すればよく、経済性などの観点から1.2〜3
モル程度が好ましい。
The amount of the guanidination reagent to be used is 0.5 mol or more, preferably 1 mol or more, based on the compound of the general formula
A molar level is preferable.

操作性および収率の面から見てシアナミドはグ
アニジノ化剤としてより好ましい。
From the viewpoint of operability and yield, cyanamide is more preferable as a guanidination agent.

一般式〔〕におけるR2の保護基としては、
アミノ基の保護基に使用されるものであれば特に
制限はなく、ホルミル基、ハロゲノ低級アルキル
カルボニル基(例えばトリフルオロアセチル基ま
たはフロロアセチル基)、フタリル基等のアシル
基、置換基を有してもよい低級アルキルオキシカ
ルボニル基(例えばtert−ブチルオキシカルボニ
ル基、ベンジルオキシカルボニル基、低級アルコ
キシ置換ベンジルオキシカルボニル基、ハロゲノ
置換ベンジルオキシカルボニル基、ニトロ置換ベ
ンジルオキシカルボニル基等)等があげられる。
As the protecting group for R 2 in the general formula [],
There is no particular restriction as long as it is used as a protecting group for an amino group, and it has an acyl group such as a formyl group, a halogeno lower alkylcarbonyl group (for example, a trifluoroacetyl group or a fluoroacetyl group), a phthalyl group, or a substituent. Examples include lower alkyloxycarbonyl groups (eg, tert-butyloxycarbonyl group, benzyloxycarbonyl group, lower alkoxy-substituted benzyloxycarbonyl group, halogeno-substituted benzyloxycarbonyl group, nitro-substituted benzyloxycarbonyl group, etc.).

R1がセリン残基の場合、そのヒドロキシル基
の保護は必須ではないが保護した方が好ましい。
保護基としてはヒドロキシル基の保護基ならば差
しつかえないがなかでもベンジル基が好ましい。
When R 1 is a serine residue, protection of its hydroxyl group is not essential, but it is preferable.
As a protecting group, any protecting group for a hydroxyl group may be used, but a benzyl group is particularly preferred.

かくして得られる下記一般式〔′〕の10−〔N
−(ω−(4−グアニジノフエニル)アシル)アミ
ノアシル〕−1,5−ジ保護−1,5,10−トリ
アザデカン (式中R′1,R2およびmは前記に同じである。) から保護基であるR2を除去するR′が保護基を有
する場合はその保護基も除去することにより一般
式〔〕の10−〔N−(ω−(4−グアニジノフエ
ニル)アシル)アミノアシル〕−1,5,10−ト
リアザデカンへ容易に導くことができる。
10-[N of the following general formula ['] obtained in this way
-(ω-(4-guanidinophenyl)acyl)aminoacyl]-1,5-diprotected-1,5,10-triazadecane (In the formula, R′ 1 , R 2 and m are the same as above.) If R , which is a protecting group, is removed from the general formula [] can be easily led to 10-[N-(ω-(4-guanidinophenyl)acyl)aminoacyl]-1,5,10-triazadecane.

本発明の原料として用いる一般式〔〕の化合
物は文献未載の新規化合物であり、 一般式 〔式中R′1,R2およびmは前記に同じ、R3はR2
と選択的に脱離可能なアミノ基の保護基を示す。〕 で表わされる10−〔N−(ω−(4−保護アミノフ
エニル)アシル)アミノアシル〕−1,5−ジ保
護−1,5,10−トリアザデカンの保護基R3
みを公知の方法により選択的に除去することによ
り合成される。
The compound of the general formula [ ] used as a raw material of the present invention is a new compound that has not been described in any literature, and the compound has the general formula [In the formula, R′ 1 , R 2 and m are the same as above, R 3 is R 2
indicates a selectively removable protecting group for an amino group. ] Only the protecting group R 3 of 10-[N-(ω-(4-protected aminophenyl)acyl)aminoacyl]-1,5-diprotected-1,5,10-triazadecane is selectively removed by a known method. It is synthesized by removing .

一般式〔〕で表わされる化合物もまた新規化
合物であり、一般式 〔式中R3およびmは前記に同じ〕 で表わされるω−保護アミノフエニル脂肪酸ある
いはその反応性誘導体と 一般式 〔式中R′1,R2は前記に同じ〕 で表わされる10−アミノアシル−1,5−ジ保護
−1,5,10−トリアザデカンとの縮合により合
成される。
The compound represented by the general formula [] is also a new compound, and the compound represented by the general formula [In the formula, R 3 and m are the same as above] ω-protected aminophenyl fatty acid or its reactive derivative represented by the general formula [In the formula, R' 1 and R 2 are the same as above] It is synthesized by condensation with 10-aminoacyl-1,5-diprotected-1,5,10-triazadecane.

アミノ基の保護基R3は、同じアミノ基の保護
基であるR2を残して除去できる保護基であれば
特に問題はなく、ペプチド化学で常用されるアミ
ノ基の保護基の中から先の条件をみたす組み合せ
を選べばよい。例を上げれば、 ベンジルオキシカルボニル基(以下Z基とい
う)とtert−ブチルオキシカルボニル基(以下
BOC基という。)、 Z基とホルミル(以下HCO基という。)、 Z基とトリフルオロアセチル基(以下TFA基
という)、 Z基とp−メトキシベンジルオキシカルボニル
基(以下単にp−MZ基と略す。)、 BOC基とHCO基、 BOC基とTFA基、 BOC基とp−置換(Cl,Br,NO2等)Z基、 TFA基とp−MZ基、 TFA基とp−置換(Cl,Br,NO2等)Z基、 p−MZ基とp−置換(Cl,Br,NO2等)Z
基。
There is no particular problem with the protecting group R 3 for the amino group as long as it can be removed leaving R 2 , which is the protecting group for the same amino group. All you have to do is choose a combination that satisfies the conditions. For example, benzyloxycarbonyl group (hereinafter referred to as Z group) and tert-butyloxycarbonyl group (hereinafter referred to as Z group)
It is called BOC group. ), Z group and formyl (hereinafter referred to as HCO group), Z group and trifluoroacetyl group (hereinafter referred to as TFA group), Z group and p-methoxybenzyloxycarbonyl group (hereinafter simply referred to as p-MZ group), BOC group and HCO group, BOC group and TFA group, BOC group and p-substituted (Cl, Br, NO 2 etc.) Z group, TFA group and p-MZ group, TFA group and p-substituted (Cl, Br, NO 2 etc.) 2, etc.) Z group, p-MZ group and p-substitution (Cl, Br, NO 2 , etc.) Z
Base.

これらはR2,R3いずれにも用いることができ
る。またR3としてフタリル基(以下pht基と略
す。)を用いR2としてZ基p−MZ基、p−置換
(Cl,Br,NO2等)Z基Boc基およびHCO基等を
用いることもできる。しかしかならずしもここで
あげたものに限定されるものではない。
These can be used for both R 2 and R 3 . Furthermore, a phthalyl group (hereinafter abbreviated as pht group) may be used as R 3 and a Z group, p-MZ group, p-substituted ( Cl, Br, NO 2, etc.) Z group, Boc group, HCO group, etc. may be used as R 2. can. However, they are not necessarily limited to those listed here.

一般式〔〕のω−保護アミノフエニル脂肪酸
と一般式〔〕の10−アミノアシル−1,5−ジ
保護−1,5,10−トリアザデカンとの縮合はペ
プチド結合形成に使用される通常の方法が使用で
きる。すなわち、ジシクロヘキシルカルボジイミ
ド(以下DCCという。)、1−エチル−3−(3−
ジメチルアミノプロピル)−カルボジイミドなど
を用いるカルボジイミド法、ヒドラジドからのア
ジド法、クロル炭酸エチル、クロル炭酸イソブチ
ルなどを用いる混合酸無水物法、シアノメチルエ
ステル、ビニルエステル、チオフエニルエステ
ル、ヒドロキシコハク酸イミドエステルなどの活
性エステル法、アセトキシム、シクロヘキサノン
オキシムなどを用いるO−アシルヒドロキシルア
ミン誘導体法、カルボニルジイミダゾールなどを
用いるN−アシル化合物法などがあげられる。
The condensation of the ω-protected aminophenyl fatty acid of the general formula [] with the 10-aminoacyl-1,5-diprotected-1,5,10-triazadecane of the general formula [] can be carried out by the usual method used for peptide bond formation. can. That is, dicyclohexylcarbodiimide (hereinafter referred to as DCC), 1-ethyl-3-(3-
(dimethylaminopropyl)-carbodiimide, azide method from hydrazide, mixed acid anhydride method using ethyl chlorocarbonate, isobutyl chlorocarbonate, etc., cyanomethyl ester, vinyl ester, thiophenyl ester, hydroxysuccinimide Examples include an active ester method using esters, an O-acylhydroxylamine derivative method using acetoxime, cyclohexanone oxime, etc., and an N-acyl compound method using carbonyldiimidazole.

また縮合に用いる溶媒としては通常のペプチド
結合形成反応に用いられる溶媒を使用できる。た
とえばジエチルエーテル、テトラヒドロフラン、
ジオキサンなどのエーテル類、酢酸エチルなどの
エステル類、アセトン、メチルエチルケトンなど
のケトン類、塩化メチレン、クロロホルムなどの
ハロゲン化炭化水素類、ジメチルホルムアミド、
ジメチルアセトアミドなどのアミド類、アセトニ
トリルなどのニトリル類などが使用できる。縮合
により得られる一般式〔〕の10−〔N−(ω−
(4−保護アミノフエニル)アシル)アミノアシ
ル〕−1,5−ジ保護−1,5,10−トリアザデ
カンは水に不溶であるので、その単離法としては
水と混和しない有機溶媒による抽出が簡便かつ効
率的であり、酸および塩基による通常の洗浄のみ
で充分高純度品を得ることができる。次いで得ら
れた一般式〔〕の化合物中のR3を公知の方法
により除去することにより一般式〔〕で表わさ
れるトリアザデカン誘導体を合成することができ
る。
Further, as the solvent used for the condensation, a solvent used in a normal peptide bond forming reaction can be used. For example, diethyl ether, tetrahydrofuran,
Ethers such as dioxane, esters such as ethyl acetate, ketones such as acetone and methyl ethyl ketone, halogenated hydrocarbons such as methylene chloride and chloroform, dimethylformamide,
Amides such as dimethylacetamide, nitrites such as acetonitrile, etc. can be used. 10-[N-(ω-
Since (4-protected aminophenyl)acyl)aminoacyl]-1,5-diprotected-1,5,10-triazadecane is insoluble in water, extraction with an organic solvent that is immiscible with water is a simple and convenient method for its isolation. It is efficient, and a product of high purity can be obtained by simply washing with acids and bases. Then, by removing R 3 in the obtained compound of general formula [] by a known method, a triazadecane derivative represented by general formula [] can be synthesized.

一般式〔〕の化合部の具体的な例としては先
述の保護基を有する化合物があげられるがなかで
も代表的化合物としては下記のものがあげられ
る。
Specific examples of the compound moiety of the general formula [] include the compounds having the aforementioned protecting groups, and among them, the following are representative compounds.

なお、以後化合物名において下記の略号を用い
るものとする。
Note that the following abbreviations will be used in compound names hereinafter.

アミノフエニル=A−Ph アミノアシル=A−Acyl トリアザデカン=TAD グアニジノフエニル=Gu−Ph ベンジル基=Bzl ベンジルオキシカルボニル=Z ジベンジルオキシカルボニル=di−Z p−メトキシベンジルオキシカルボニル=p−
MZ ジp−メトキシベンジルオキシカルボニル=di
−p−MZ ジ−p−クロルベンジルオキシカルボニル=di
−p−CLZ tert−ブチルオキシカルボニル=Boc グリシル=Gly フタリル=Pht セリル=Ser ジシクロヘキシルカルボジイミド=DCC 10−〔N−(4−(4−A−Ph)ブタノイル)Gly〕
−1,5−di−Z−1,5,10−TAD 10−〔N−(4−(4−A−Ph)ブタノイル)−L
−Ser〕−1,5−di−Z−1,5,10−TAD 10−〔N−(4−(4−A−Ph)ブタノイル)−O
−Bzl−L−Ser〕−1,5−di−Z−1,5,10
−TAD 10−〔N−(4−(4−A−Ph)ブタノイル)−O
−tert−ブチル−L−Ser〕−1,5−di−Z−
1,5,10−TAD 10−〔N−(5−(4−A−Ph)ペンタノイル)
Gly〕−1,5−di−Z−1,5,10−TAD 10−〔N−(5−(4−A−Ph)ペンタノイル)−
L−Ser〕−1,5−di−Z−1,5,10−TAD 10−〔N−(5−(4−A−Ph)ペンタノイル)−
O−Z−L−Ser〕−1,5−di−Z−1,5,10
−TAD 10−〔N−(5−(4−A−Ph)ペンタノイル)−
O−tert−ブチル−L−Ser〕−1,5−di−Z−
1,5,10−TAD 10−〔N−(6−(4−A−Ph)ヘキサノイル)
Gly〕−1,5−di−Z−1,5,10−TAD 10−〔N−(6−(4−A−Ph)ヘキサノイル)−
L−Ser〕−1,5−di−Z−1,5,10−TAD 10−〔N−(6−(4−A−Ph)ヘキサノイル)−
O−Z−L−Ser〕−1,5−di−Z−1,5,10
−TAD 10−〔N−(6−(4−A−Ph)ヘキサノイル)−
O−tert−ブチル−L−−Ser〕−1,5−di−Z
−1,5,10−TAD 10−〔N−(4−(4−A−Ph)ブタノイル)Gly〕
−1,5−ジ−Boc−1,5,10−TAD 10−〔N−(4−(4−A−Ph)ブタノイル)−L
−Ser〕−1,5−di−Boc−1,5,10−TAD 10−〔N−(4−(4−A−Ph)ブタノイル)−O
−Bzl−L−Ser〕−1,5−di−Boc−1,5,
10−TAD 10−〔N−(4−(4−A−Ph)ブタノイル)−O
−tert−ブチル−L−Ser〕−1,5−di−Boc−
1,5,10−TAD 10−〔N−(5−4−A−Ph)ペンタノイル)
Gly〕−1,5−di−Boc−1,5,10−TAD 10−〔N−(5−(4−A−Ph)ペンタノイル)−
L−Ser〕−1,5−di−Boc−1,5,10−
TAD 10−〔N−(5−(4−A−Ph)ペンタノイル)−
O−Bzl−L−Ser〕−1,5−di−Boc−1,5,
10−TAD 10−〔N−(5−(4−A−Ph)ペンタノイル)−
O−tert−ブチル−L−Ser〕−1,5−di−Boc
−1,5,10−TAD 10−〔N−(6−(4−A−Ph)ヘキサノイル)
Gly〕−1,5−di−Boc−1,5,10−TAD 10−〔N−(6−(4−A−Ph)ヘキサノイル)−
L−Ser〕−1,5−di−Boc−1,5,10−
TAD 10−〔N−(6−(4−A−Ph)ヘキサノイル)−
O−Bzl−L−Ser〕−1,5−di−Boc−1,5,
10−TAD 10−〔N−(6−(4−A−Ph)ヘキサノイル)−
O−tert−ブチル−L−Ser〕−1,5−di−Boc
−1,5,10−TAD 10−〔N−(4−(4−A−Ph)ブタノイル)Gly〕
−1,5−di−p−MZ=1,5,10−TAD 10−〔N−(4−(4−A−Ph)ブタノイル)−L
−Ser〕−1,5−di−p−MZ−1,5,10−
TAD 10−〔N−(4−(4−A−Ph)ブタノイル)−O
−Bzl−L−Ser〕−1,5−di−p−MZ−1,
5,10−TAD 10−〔N−(4−(4−A−Ph)ブタノイル−O−
p−MZ−L−Ser〕−1,5−di−p−MZ−1,
5,10−TAD 10−〔N−(5−(4−A−Ph)ペンタノイル)
Gly〕−1,5−di−p−MZ−1,5,10−
TAD 10−〔N−(5−(4−A−Ph)ペンタノイル)−
L−Ser〕−1,5−di−p−MZ−1,5,10−
TAD 10−〔N−(5−(4−A−Ph)ペンタノイル)−
O−Bzl−L−Ser〕−1,5−di−p−MZ−1,
5,10−TAD 10−〔N−(5−(4−A−Ph)ペンタノイル)−
O−P−MZ−L−Ser〕−1,5−di−p−MZ
−1,5,10−TAD 10−〔N−(6−(4−A−Ph)ヘキサノイル)
Gly〕−1,5−di−p−MZ−1,5,10−
TAD 10−〔N−(6−(4−A−Ph)ヘキサノイル)−
L−Ser〕−1,5−di−p−MZ−1,5,10−
TAD 10−〔N−(6−(4−A−Ph)ヘキサノイル)−
O−Bzl−L−Ser〕−1,5−di−p−MZ−1,
5,10−TAD 10−〔N−(6−(4−A−Ph)ヘキサノイル)−
O−p−MZ−L−Ser〕−1,5−di−p−MZ
−1,5,10−TAD 10−〔N−(4−(4−A−Ph)ブタノイル)Gly〕
−1,5−di−p−ClZ−1,5,10−TAD なお一般式〔〕の10−アミノアシル−1,5
−ジ保護−1,5,10−トリアザデカンは次のよ
うにして合成することができる。
Aminophenyl = A-Ph Aminoacyl = A-Acyl Triazadecane = TAD Guanidinophenyl = Gu-Ph Benzyl group = Bzl Benzyloxycarbonyl = Z Dibenzyloxycarbonyl = di-Z p-Methoxybenzyloxycarbonyl = p-
MZ Di p-methoxybenzyloxycarbonyl=di
-p-MZ di-p-chlorobenzyloxycarbonyl=di
-p-CLZ tert-butyloxycarbonyl=Boc Glycyl=Gly Phthalyl=Pht Seryl=Ser Dicyclohexylcarbodiimide=DCC 10-[N-(4-(4-A-Ph)butanoyl)Gly]
-1,5-di-Z-1,5,10-TAD 10-[N-(4-(4-A-Ph)butanoyl)-L
-Ser]-1,5-di-Z-1,5,10-TAD 10-[N-(4-(4-A-Ph)butanoyl)-O
-Bzl-L-Ser〕-1,5-di-Z-1,5,10
-TAD 10-[N-(4-(4-A-Ph)butanoyl)-O
-tert-butyl-L-Ser]-1,5-di-Z-
1,5,10-TAD 10-[N-(5-(4-A-Ph)pentanoyl)
Gly]-1,5-di-Z-1,5,10-TAD 10-[N-(5-(4-A-Ph)pentanoyl)-
L-Ser]-1,5-di-Z-1,5,10-TAD 10-[N-(5-(4-A-Ph)pentanoyl)-
O-Z-L-Ser]-1,5-di-Z-1,5,10
-TAD 10- [N-(5-(4-A-Ph)pentanoyl)-
O-tert-butyl-L-Ser]-1,5-di-Z-
1,5,10-TAD 10-[N-(6-(4-A-Ph)hexanoyl)
Gly]-1,5-di-Z-1,5,10-TAD 10-[N-(6-(4-A-Ph)hexanoyl)-
L-Ser]-1,5-di-Z-1,5,10-TAD 10-[N-(6-(4-A-Ph)hexanoyl)-
O-Z-L-Ser]-1,5-di-Z-1,5,10
-TAD 10-[N-(6-(4-A-Ph)hexanoyl)-
O-tert-butyl-L--Ser]-1,5-di-Z
-1,5,10-TAD 10-[N-(4-(4-A-Ph)butanoyl)Gly]
-1,5-di-Boc-1,5,10-TAD 10-[N-(4-(4-A-Ph)butanoyl)-L
-Ser]-1,5-di-Boc-1,5,10-TAD 10-[N-(4-(4-A-Ph)butanoyl)-O
-Bzl-L-Ser〕-1,5-di-Boc-1,5,
10-TAD 10-[N-(4-(4-A-Ph)butanoyl)-O
-tert-butyl-L-Ser]-1,5-di-Boc-
1,5,10-TAD 10-[N-(5-4-A-Ph)pentanoyl)
Gly]-1,5-di-Boc-1,5,10-TAD 10-[N-(5-(4-A-Ph)pentanoyl)-
L-Ser〕-1,5-di-Boc-1,5,10-
TAD 10-[N-(5-(4-A-Ph)pentanoyl)-
O-Bzl-L-Ser]-1,5-di-Boc-1,5,
10-TAD 10-[N-(5-(4-A-Ph)pentanoyl)-
O-tert-butyl-L-Ser]-1,5-di-Boc
-1,5,10-TAD 10-[N-(6-(4-A-Ph)hexanoyl)
Gly]-1,5-di-Boc-1,5,10-TAD 10-[N-(6-(4-A-Ph)hexanoyl)-
L-Ser〕-1,5-di-Boc-1,5,10-
TAD 10-[N-(6-(4-A-Ph)hexanoyl)-
O-Bzl-L-Ser]-1,5-di-Boc-1,5,
10-TAD 10-[N-(6-(4-A-Ph)hexanoyl)-
O-tert-butyl-L-Ser]-1,5-di-Boc
-1,5,10-TAD 10-[N-(4-(4-A-Ph)butanoyl)Gly]
-1,5-di-p-MZ=1,5,10-TAD 10-[N-(4-(4-A-Ph)butanoyl)-L
-Ser〕-1,5-di-p-MZ-1,5,10-
TAD 10-[N-(4-(4-A-Ph)butanoyl)-O
-Bzl-L-Ser〕-1,5-di-p-MZ-1,
5,10-TAD 10-[N-(4-(4-A-Ph)butanoyl-O-
p-MZ-L-Ser]-1,5-di-p-MZ-1,
5,10-TAD 10-[N-(5-(4-A-Ph)pentanoyl)
Gly]-1,5-di-p-MZ-1,5,10-
TAD 10-[N-(5-(4-A-Ph)pentanoyl)-
L-Ser]-1,5-di-p-MZ-1,5,10-
TAD 10-[N-(5-(4-A-Ph)pentanoyl)-
O-Bzl-L-Ser]-1,5-di-p-MZ-1,
5,10-TAD 10-[N-(5-(4-A-Ph)pentanoyl)-
O-P-MZ-L-Ser〕-1,5-di-p-MZ
-1,5,10-TAD 10-[N-(6-(4-A-Ph)hexanoyl)
Gly]-1,5-di-p-MZ-1,5,10-
TAD 10-[N-(6-(4-A-Ph)hexanoyl)-
L-Ser]-1,5-di-p-MZ-1,5,10-
TAD 10-[N-(6-(4-A-Ph)hexanoyl)-
O-Bzl-L-Ser]-1,5-di-p-MZ-1,
5,10-TAD 10-[N-(6-(4-A-Ph)hexanoyl)-
O-p-MZ-L-Ser]-1,5-di-p-MZ
-1,5,10-TAD 10-[N-(4-(4-A-Ph)butanoyl)Gly]
-1,5-di-p-ClZ-1,5,10-TAD 10-aminoacyl-1,5 of general formula []
-Diprotected-1,5,10-triazadecane can be synthesized as follows.

すなわち、一般式 〔式中R2は前記に同じである。〕 で表わされる1,5−ジ保護−1,5,10−トリ
アザデカンに、一般式 R4−OH 〔〕 〔式中R4はR2とは異なる保護基でアミノ基が
保護されているグリシンまたはセリンのα−カル
ボキシル基からヒドロキシル基を除いた残基を示
す。〕 で表わされるN−保護α−またはω−アミノ酸を
縮合させて、一般式 〔式中R2およびR4は前記に同じである。〕 で表わされる10−(N−保護アミノアシル)−1,
5−ジ保護−1,5,10−トリアザデカンを得、
ついでこの化合物より、R4のアミノ酸残基中の
アミノ基の保護基を常法により除去して、 〔式中R′1,およびR2は前記に同じである。〕 で表わされる10−アミノアシル−1,5−ジ保護
−1,5,10−トリアザデカンを得ることができ
る。
That is, the general formula [In the formula, R 2 is the same as above. ] 1,5-diprotected-1,5,10-triazadecane represented by the general formula R 4 -OH [] [wherein R 4 is glycine whose amino group is protected with a protecting group different from R 2 Alternatively, it represents a residue obtained by removing the hydroxyl group from the α-carboxyl group of serine. ] By condensing N-protected α- or ω-amino acids represented by the general formula [In the formula, R 2 and R 4 are the same as above. ] 10-(N-protected aminoacyl)-1,
5-diprotected-1,5,10-triazadecane was obtained,
Next, from this compound, the protecting group of the amino group in the amino acid residue of R4 was removed by a conventional method, [In the formula, R′ 1 and R 2 are the same as above. ] 10-Aminoacyl-1,5-diprotected-1,5,10-triazadecane can be obtained.

以下本発明を実施例において具体的に説明する
が本発明は実施例に限定されるものではない。
EXAMPLES The present invention will be specifically explained below with reference to Examples, but the present invention is not limited to the Examples.

なお実施例中に記載した薄層クロマトグラフイ
(TLC)のRf値はシリカゲル(シリカゲル
60F254、厚さ0.25mmプレート:メルク社製)を用
い、実施例中に記載した展開溶媒で約8cm展開
し、原点から目的物のスポツトの中心までの距離
を原点から展開溶媒の先端までの距離で割つて算
出した。検出はUV(2537Å)、ニンヒドリンおよ
び坂口試薬を用いて行つた。
Note that the Rf values for thin layer chromatography (TLC) described in the examples are for silica gel (silica gel).
60F 254 , 0.25 mm thick plate (manufactured by Merck & Co., Ltd.), was developed for about 8 cm using the developing solvent described in the example, and the distance from the origin to the center of the target spot was measured from the origin to the tip of the developing solvent. Calculated by dividing by distance. Detection was performed using UV (2537 Å), ninhydrin and Sakaguchi reagent.

NMRは日本電子JNM−PMX60型、IRスペク
トルは日本分光A−202型により測定した。
NMR was measured using JEOL JNM-PMX60 model, and IR spectrum was measured using JASCO Model A-202.

実施例 1 イ 10−{N−〔4−(4−Boc−A−Ph)ブタノ
イル〕Gly}−1,5−di−Z−1,5,10−
TAD 白色結晶の4−(4−Boc−A−Ph)酪酸1.23
g(4.4mmol)をテトラヒドロフラン20mlに溶か
し、氷冷下DCC1.09g(5.28mmol)とN−ヒド
ロキシコハク酸イミド0.61g(5.28mmol)を加
え、室温で一夜反応させる。析出したN,N′−
ジシクロヘキシル尿素を別し、液はそのまま
次の反応に使用する。淡黄色油状の10−Gly−
1,5−di−Z−1,5,10−TAD1.96g
(4.16mmol)をテトラヒドロフラン15mlに溶か
し、氷冷下トリエチルアミン0.54g(5.28mmol)
を加え、次いで上に述べた4−(4−Boc−A−
Ph)酪酸N−ヒドロキシコハク酸イミドエステ
ルのテトラヒドロフラン溶液を加え、室温で一夜
反応させる。反応液にN,N−ジエチル−1,3
−プロパンジアミン1mlを加え、室温で1時間撹
拌後、反応液を減圧濃縮する。油状の残渣を酢酸
エチル150mlに溶かし、5%リン酸、5%炭酸ナ
トリウム水溶液で順次洗浄し、有機層を無水硫酸
ナトリウムで乾燥し、乾燥剤を別後液を減圧
濃縮すると、淡黄色油状物4.1gが得られる。こ
れをシリカゲル(ワコーゲルC−200 )200mlを
充填したカラムに付し、クロロホルム−メタノー
ル(40:1v/v)の混液で展開し、目的物を含
むフラクシヨンを集め、減圧で濃縮すると淡黄色
油状の目的物2.05g(収率67.3%)が得られる。
Example 1 A 10-{N-[4-(4-Boc-A-Ph)butanoyl]Gly}-1,5-di-Z-1,5,10-
TAD White crystalline 4-(4-Boc-A-Ph)butyric acid 1.23
g (4.4 mmol) was dissolved in 20 ml of tetrahydrofuran, 1.09 g (5.28 mmol) of DCC and 0.61 g (5.28 mmol) of N-hydroxysuccinimide were added under ice cooling, and the mixture was allowed to react overnight at room temperature. Precipitated N, N'-
Separate the dicyclohexyl urea and use the liquid as it is for the next reaction. Pale yellow oily 10−Gly−
1,5-di-Z-1,5,10-TAD1.96g
(4.16 mmol) was dissolved in 15 ml of tetrahydrofuran, and 0.54 g (5.28 mmol) of triethylamine was prepared under ice cooling.
and then the 4-(4-Boc-A-
Ph) Add a solution of butyric acid N-hydroxysuccinimide ester in tetrahydrofuran and react overnight at room temperature. N,N-diethyl-1,3 to the reaction solution
- Add 1 ml of propanediamine, stir at room temperature for 1 hour, and then concentrate the reaction solution under reduced pressure. The oily residue was dissolved in 150 ml of ethyl acetate, washed successively with 5% phosphoric acid and 5% sodium carbonate aqueous solution, the organic layer was dried over anhydrous sodium sulfate, the desiccant was removed, and the liquid was concentrated under reduced pressure to form a pale yellow oil. 4.1g is obtained. This was applied to a column packed with 200 ml of silica gel (Wako Gel C-200), developed with a mixture of chloroform and methanol (40:1 v/v), and fractions containing the target product were collected and concentrated under reduced pressure to form a pale yellow oil. 2.05 g (yield 67.3%) of the target product is obtained.

NMR(CDCl3) δ=1.1〜2.4(b,10H),1.43(s,9H),2.4〜
2.8(b,2H),2.8〜3.5(b,8H),3.6〜4.1
(bd,2H),5.2〜7.7(b,4H),6.8〜7.4(m,
4H),7.3(s,14H). IR(KBr) ν(cm-1)=3330,2950,1700,1680,1525,
1475,1430,1420,1370,1315,1245,
1160,1050,1025,735. TLC(クロロホルム:メタノール=10:1v/
v) Rf=0.29 ロ 10−{N−〔4−(4−A−Ph)ブタノイル〕
Gly}−1,5−di−Z−1,5,10−TAD 10−{N−〔4−(4−Boc−A−Ph)ブタノイ
ル〕Gly}−1,5−di−Z−1,5,10−
TAD1.17g(1.6mmol)に氷冷下トリフルオロ
酢酸5mlを加えて溶かし、室温で1時間反応させ
る。反応液を減圧で濃縮し、得られた油状物を酢
酸エチル100mlに溶かし、5%炭酸ナトリウム水
溶液、飽和食塩水で順次洗浄し、有機層を無水硫
酸ナトリウムで乾燥する。乾燥剤を別後液を
減圧濃縮すると淡黄色油状の目的物0.85g(収率
84.2%)が得られる。
NMR ( CDCl3 ) δ=1.1~2.4 (b, 10H), 1.43 (s, 9H), 2.4~
2.8 (b, 2H), 2.8~3.5 (b, 8H), 3.6~4.1
(bd, 2H), 5.2-7.7 (b, 4H), 6.8-7.4 (m,
4H), 7.3(s, 14H). IR (KBr) ν (cm -1 ) = 3330, 2950, 1700, 1680, 1525,
1475, 1430, 1420, 1370, 1315, 1245,
1160, 1050, 1025, 735. TLC (Chloroform: Methanol = 10:1v/
v) Rf=0.29 b 10-{N-[4-(4-A-Ph)butanoyl]
Gly}-1,5-di-Z-1,5,10-TAD 10-{N-[4-(4-Boc-A-Ph)butanoyl]Gly}-1,5-di-Z-1, 5,10−
Add 5 ml of trifluoroacetic acid to 1.17 g (1.6 mmol) of TAD under ice-cooling to dissolve and react at room temperature for 1 hour. The reaction solution is concentrated under reduced pressure, and the resulting oil is dissolved in 100 ml of ethyl acetate, washed successively with a 5% aqueous sodium carbonate solution and saturated brine, and the organic layer is dried over anhydrous sodium sulfate. After removing the drying agent, the liquid was concentrated under reduced pressure to obtain 0.85 g of the target product as a pale yellow oil (yield:
84.2%).

NMR(CDCl3) δ=1.1〜2.3(b,10H),2.3〜2.6(b,2H),
2.7〜3.5(b,8H),3.3〜4.1(b,2H),3.6
〜4.0(bd,2H),4.8〜7.5(b,3H),5.1(s,
4H),6.53(d,2H,J=8Hz),6.93(d,
2H,J=8Hz),7.33(s,10H). IR(Neat) ν(cm-1)=3325,2950,1685,1545,1520,
1475,1450,1425,1260,1215,1150,
1025. TLC(クロロホルム:メタノール=10:1v/
v) Rf=0.32. ハ 10−{N−〔4−(4−Gu−Ph)ブタノイル〕
Gly}−1,5−di−Z−1,5,10−TAD塩
酸塩 10−{N−〔4−(4−A−Ph)ブタノイル〕
Gly}−1,5−di−Z−1,5,10−TAD100mg
(0.16mmol)をエタノール2mlに溶かし、1−ア
ミジノ−3,5−ジメチルピラゾール硝酸塩48mg
(0.24mmol)とN,N−ジイソプロピルエチルア
ミン39mg(0.3mmol)を加え90℃の油浴中で48時
間反応させる。反応液を減圧濃縮し、得られた残
渣に酢酸エチル30mlとエタノール6mlを加えて溶
かし、5%炭酸ナトリウム水溶液、1規定塩酸、
飽和食塩水で順次洗浄する。有機層を無水硫酸ナ
トリウムで乾燥し、乾燥剤を別後減圧濃縮す
る。得られた残渣をシリカゲル60 (メルク社
製)4mlを充填したカラムに付し、クロロホルム
−メタノール−17%アンモニア水(6:1.5:
0.25v/v)の混液で展開し、目的物を含むフラ
クシヨンを集め、減圧濃縮すると淡黄色油状物45
mg(収率40.2%)が得られる。
NMR ( CDCl3 ) δ=1.1~2.3 (b, 10H), 2.3~2.6 (b, 2H),
2.7~3.5 (b, 8H), 3.3~4.1 (b, 2H), 3.6
~4.0 (bd, 2H), 4.8 ~ 7.5 (b, 3H), 5.1 (s,
4H), 6.53 (d, 2H, J=8Hz), 6.93 (d,
2H, J=8Hz), 7.33(s, 10H). IR (Neat) ν (cm -1 ) = 3325, 2950, 1685, 1545, 1520,
1475, 1450, 1425, 1260, 1215, 1150,
1025. TLC (Chloroform: Methanol = 10:1v/
v) Rf=0.32. C 10-{N-[4-(4-Gu-Ph)butanoyl]
Gly}-1,5-di-Z-1,5,10-TAD hydrochloride 10-{N-[4-(4-A-Ph)butanoyl]
Gly}-1,5-di-Z-1,5,10-TAD100mg
(0.16 mmol) was dissolved in 2 ml of ethanol, and 48 mg of 1-amidino-3,5-dimethylpyrazole nitrate was added.
(0.24 mmol) and 39 mg (0.3 mmol) of N,N-diisopropylethylamine were added and allowed to react in an oil bath at 90°C for 48 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was dissolved by adding 30 ml of ethyl acetate and 6 ml of ethanol, and dissolved in 5% aqueous sodium carbonate solution, 1N hydrochloric acid,
Wash sequentially with saturated saline. The organic layer is dried over anhydrous sodium sulfate, and after removing the desiccant, it is concentrated under reduced pressure. The obtained residue was applied to a column packed with 4 ml of silica gel 60 (manufactured by Merck & Co., Ltd.) and mixed with chloroform-methanol-17% aqueous ammonia (6:1.5:
0.25v/v), collect the fractions containing the target product, and concentrate under reduced pressure to obtain a pale yellow oil.
mg (yield 40.2%) is obtained.

NMR(CDCl3) δ=1.1〜2.8(b,12H),2.8〜3.6(b,8H),
3.6〜4.1(b,2H),4.8〜8.8(b,8H),5.03
(bs,4H),7.23(s,14H). IR(HBr) ν(cm-1)=3310,2950,1670,1540,1515,
1450,1420,1260,1210,1150,1020. TLC(クロロホルム:メタノール:17%アン
モニア水=6:1.5:0.25v/v) Rf=0.24. ニ 10−{N−〔4−(4−Gu−Ph)ブタノイル〕
Gly}−1,5,10−TAD3塩酸塩 淡黄色の10−{N−〔4−(4−Gu−Ph)ブタ
ノイル〕Gly}−1,5−di−Z−1,5,10−
TAD塩酸塩0.42g(0.59mmol)を酢酸5mlとメ
タノール5mlの混液に溶かし、パラジウム黒50mg
を加えて50℃に加温し、常圧で12時間接触還元を
行う。反応後触媒を別し液を減圧濃縮する
と、油状物0.27gが得られる。
NMR ( CDCl3 ) δ=1.1~2.8 (b, 12H), 2.8~3.6 (b, 8H),
3.6-4.1 (b, 2H), 4.8-8.8 (b, 8H), 5.03
(bs, 4H), 7.23 (s, 14H). IR (HBr) ν (cm -1 ) = 3310, 2950, 1670, 1540, 1515,
1450, 1420, 1260, 1210, 1150, 1020. TLC (chloroform: methanol: 17% ammonia water = 6: 1.5: 0.25 v/v) Rf = 0.24. Ph) Butanoyl]
Gly}-1,5,10-TAD3 hydrochloride Pale yellow 10-{N-[4-(4-Gu-Ph)butanoyl]Gly}-1,5-di-Z-1,5,10-
Dissolve 0.42 g (0.59 mmol) of TAD hydrochloride in a mixture of 5 ml of acetic acid and 5 ml of methanol, and dissolve 50 mg of palladium black.
was added, heated to 50°C, and subjected to catalytic reduction at normal pressure for 12 hours. After the reaction, the catalyst was separated and the liquid was concentrated under reduced pressure to obtain 0.27 g of an oily substance.

この油状物を蒸留水1.5mlに溶かし、CM−セフ
アデツクス C−25(Na+)30mlを充填したカラ
ムに付し、蒸留水150mlと1.0M塩化ナトリウム水
溶液150mlとの間のグラジエント溶出法で溶出し、
目的物を含むフラクシヨンを集め、減圧で濃縮乾
固し、乾固物にメタノールを加えて不溶の塩化ナ
トリウムを別する。この操作を2回くり返す。
残存する少量の塩化ナトリウムを除去するために
得られた油状物をメタノール1mlに溶かし、セフ
アデツクス LH−20 14mlを充填したカラムに
付し、メタノールで溶出し、目的物を含むフラク
シヨンを集め減圧で濃縮する。さらに少量の不純
物を除去するために得られた油状物を蒸留水1ml
に溶かし、三菱化成HP−20 10mlを充填したカ
ラムに付し、蒸留水で溶出し、目的物を含むフラ
クシヨンを集め、減圧で濃縮する。得られた油状
物をエタノールより再結晶し、目的物113mg(収
率34.7%)が得られる。
This oil was dissolved in 1.5 ml of distilled water, applied to a column packed with 30 ml of CM-Sephadex C-25 (Na + ), and eluted using a gradient elution method between 150 ml of distilled water and 150 ml of 1.0 M aqueous sodium chloride solution. ,
Fractions containing the target product are collected, concentrated to dryness under reduced pressure, and methanol is added to the dried product to separate insoluble sodium chloride. Repeat this operation twice.
To remove the remaining small amount of sodium chloride, the resulting oil was dissolved in 1 ml of methanol, applied to a column packed with 14 ml of Cephadex LH-20, eluted with methanol, and fractions containing the target product were collected and concentrated under reduced pressure. do. To further remove a small amount of impurities, add 1 ml of distilled water to the resulting oil.
The target product was dissolved in a column packed with 10 ml of Mitsubishi Kasei HP-20 and eluted with distilled water. Fractions containing the target product were collected and concentrated under reduced pressure. The obtained oil was recrystallized from ethanol to obtain 113 mg (yield 34.7%) of the desired product.

Mp 153−155℃ NMR(DMSO−d6) δ=1.1〜2.5(b,12H),2.5〜3.3(b,8H),
3.5〜3.9(bd,2H),6.9〜7.4(m,4H),7.2
〜7.7(b,4H),7.7〜8.3(b,3H),8.3〜
10.0(b,5H). IR(KBr) ν(cm-1)=3280,3095,2950,2875,1670,
1630,1615,1565,1530,1510,1440,
1265. TLC(n−プロパノール:ピリジン:水:酢
酸=6:4:3:2v/v) Rf=0.26. 実施例 2 イ 10−{N−〔4−(4−Z−A−Ph)ブタノイ
ル〕Gly}−1,5−di−Boc−1,5,10−
TAD 白色結晶の4−(4−Z−A−Ph)酪酸0.7g
(2.23mmol)をテトラヒドロフラン20mlに溶か
し、氷冷下DCC0.6g(2.9mmol)とN−ヒドロ
キシコハク酸イミド0.33g(2.9mmol)を加え、
室温で一夜反応させる。析出したN,N′−ジシ
クロヘキシル尿素を別し、液はそのまま次の
反応に使用する。
Mp 153-155℃ NMR (DMSO- d6 ) δ=1.1~2.5 (b, 12H), 2.5~3.3 (b, 8H),
3.5-3.9 (bd, 2H), 6.9-7.4 (m, 4H), 7.2
~7.7 (b, 4H), 7.7~8.3 (b, 3H), 8.3~
10.0 (b, 5H). IR (KBr) ν (cm -1 ) = 3280, 3095, 2950, 2875, 1670,
1630, 1615, 1565, 1530, 1510, 1440,
1265. TLC (n-propanol:pyridine:water:acetic acid = 6:4:3:2v/v) Rf=0.26. Example 2 A 10-{N-[4-(4-Z-A-Ph)butanoyl ]Gly}-1,5-di-Boc-1,5,10-
TAD White crystalline 4-(4-Z-A-Ph)butyric acid 0.7g
(2.23 mmol) was dissolved in 20 ml of tetrahydrofuran, and under ice-cooling, 0.6 g (2.9 mmol) of DCC and 0.33 g (2.9 mmol) of N-hydroxysuccinimide were added.
Incubate overnight at room temperature. The precipitated N,N'-dicyclohexylurea is separated and the liquid is used as it is for the next reaction.

淡黄色油状の10−Gly−1,5−di−Boc−1,
5,10−TAD0.69g(1.71mmol)をテトラヒド
ロフラン20mlに溶かし、氷冷下トリエチルアミン
0.29g(2.23mmol)を加え、次いで上に述べた
4−(4−Z−A−Ph)酪酸N−ヒドロキシコハ
ク酸イミドエステルのテトラヒドロフラン溶液を
加え、室温で一夜反応させる。反応液にN,N−
ジエチル−1,3−プロパンジアミン1mlを加
え、室温で1時間撹拌後、反応液を減圧濃縮す
る。
10-Gly-1,5-di-Boc-1, pale yellow oil
Dissolve 0.69 g (1.71 mmol) of 5,10-TAD in 20 ml of tetrahydrofuran and add triethylamine under ice cooling.
0.29 g (2.23 mmol) is added, followed by the tetrahydrofuran solution of 4-(4-Z-A-Ph)butyric acid N-hydroxysuccinimide ester mentioned above, and the mixture is allowed to react overnight at room temperature. N,N- in the reaction solution
1 ml of diethyl-1,3-propanediamine was added, and after stirring at room temperature for 1 hour, the reaction solution was concentrated under reduced pressure.

油状の残渣を酢酸エチル150mlに溶かし、5%
炭酸水素ナトリウム水溶液、飽和食塩水で順次洗
浄する。有機層を無水硫酸ナトリウムで乾燥し、
乾燥剤を別後液を減圧濃縮すると淡黄色油状
物1.45gが得られる。これをシリカゲル60 (メ
ルク社製)90mlを充填したカラムに付し、クロロ
ホルム−アセトン(3:1v/v)の混液で展開
し、目的物を含むフラクシヨンを集め、減圧で濃
縮すると、淡黄色油状の目的物0.74g(収率62.2
%)が得られる。
Dissolve the oily residue in 150 ml of ethyl acetate and dilute to 5%
Wash sequentially with aqueous sodium hydrogen carbonate solution and saturated saline. The organic layer was dried with anhydrous sodium sulfate,
After removing the desiccant, the liquid was concentrated under reduced pressure to obtain 1.45 g of a pale yellow oil. This was applied to a column packed with 90 ml of silica gel 60 (manufactured by Merck & Co.), developed with a mixture of chloroform and acetone (3:1 v/v), and the fractions containing the target product were collected and concentrated under reduced pressure to form a pale yellow oil. of target product 0.74g (yield 62.2
%) is obtained.

NMR(CDCl3) δ=1.1〜2.4(b,10H),1.45(s,18H),2.4
〜2.8(b,2H),2.8〜3.5(b,8H),3.7〜
4.1(bd,2H),5.18(s,2H),4.3〜7.8(b,
4H),6.8〜7.4(m,4H),7.33(s,5H). IR(Neat) ν(cm-1)=3310,2970,2930,1670,1600,
1525,1410,1365,1310,1165,1050,830. TLC(クロロホルム:アセトン=3:1v/v) Rf=0.29. ロ 10−{N−〔4−(4−A−Ph)ブタノイル〕
Gly}−1,5−di−Boc−1,5,10−TAD 10−{N−〔4−(4−Z−A−Ph)ブタノイ
ル〕Gly}−1,5−di−Boc−1,5,10−
TAD0.43g(0.61mmol)をメタノール20mlに溶
かし、パラジウム黒30mgを加えて室温、常圧で3
時間接触還元を行う。
NMR ( CDCl3 ) δ=1.1~2.4 (b, 10H), 1.45 (s, 18H), 2.4
~2.8 (b, 2H), 2.8~3.5 (b, 8H), 3.7~
4.1 (bd, 2H), 5.18 (s, 2H), 4.3~7.8 (b,
4H), 6.8-7.4 (m, 4H), 7.33 (s, 5H). IR (Neat) ν (cm -1 ) = 3310, 2970, 2930, 1670, 1600,
1525, 1410, 1365, 1310, 1165, 1050, 830. TLC (Chloroform: Acetone = 3:1 v/v) Rf = 0.29. B 10-{N-[4-(4-A-Ph) Butanoyl]
Gly}-1,5-di-Boc-1,5,10-TAD 10-{N-[4-(4-Z-A-Ph)butanoyl]Gly}-1,5-di-Boc-1, 5,10−
Dissolve 0.43 g (0.61 mmol) of TAD in 20 ml of methanol, add 30 mg of palladium black, and stir at room temperature and normal pressure.
Perform time contact reduction.

反応後触媒を別し、液を減圧濃縮すると淡
黄色油状の目的物0.31g(収率89.3%)が得られ
る。
After the reaction, the catalyst was separated and the liquid was concentrated under reduced pressure to obtain 0.31 g (yield: 89.3%) of the target product as a pale yellow oil.

NMR(CDCl3) δ=1.1〜2.3(b,10H),1.43(s,18H),2.3
〜2.7(b,2H),2.7〜3.6(b,8H),3.2〜
3.7(b,2H),3.7〜4.0(bd,2H),4.3〜7.4
(b,3H),6.6(d,2H,J=8Hz),6.93
(d,2H,J=8Hz). IR(Neat) ν(cm-1)=3330,2970,2930,1640,1515,
1415,1360,1250,1165. TLC(クロロホルム:アセトン=3:1v/v) Rf=0.18. ハ 10−{N−〔4−(4−Gu−Ph)ブタノイル〕
Gly}−1,5−di−Boc−1,5,10−TAD
塩酸塩 10−{N−〔4−(4−A−Ph)ブタノイル〕
Gly}−1,5−Boc−1,5,10−TAD180mg
(0.32mmol)をエタノール1.5mlに溶かした溶液
に1規定塩酸0.32mlを加え、次いでシアナミド
520mg(12.36mmol)を加え、70℃で反応させる。
途中PHを4〜5に保つために1規定塩酸を添加し
ながら10時間反応させた後、減圧濃縮にて溶媒を
留去する。残渣を酢酸エチル50mlとエタノール10
mlの混液に溶かし、5%炭酸ナトリウム水溶液、
0.5規定塩酸、飽和食塩水で順次洗浄する。有機
層を無水硫酸ナトリウムで乾燥し、乾燥剤を別
後減圧濃縮する。得られた残渣をシリカゲル60
(メルク社製)8mlを充填したカラムに付し、ク
ロロホルム−メタノール(5:1v/v)の混液
で展開し、目的物を含むフラクシヨンを集め減圧
濃縮すると淡黄色油状物136mg(収率66.7%)が
得られる。
NMR (CDCl 3 ) δ=1.1~2.3 (b, 10H), 1.43 (s, 18H), 2.3
~2.7 (b, 2H), 2.7~3.6 (b, 8H), 3.2~
3.7 (b, 2H), 3.7~4.0 (bd, 2H), 4.3~7.4
(b, 3H), 6.6 (d, 2H, J=8Hz), 6.93
(d, 2H, J=8Hz). IR (Neat) ν (cm -1 ) = 3330, 2970, 2930, 1640, 1515,
1415, 1360, 1250, 1165. TLC (chloroform:acetone = 3:1v/v) Rf=0.18. Ha 10-{N-[4-(4-Gu-Ph)butanoyl]
Gly}-1,5-di-Boc-1,5,10-TAD
Hydrochloride 10-{N-[4-(4-A-Ph)butanoyl]
Gly}-1,5-Boc-1,5,10-TAD180mg
(0.32 mmol) dissolved in 1.5 ml of ethanol, add 0.32 ml of 1N hydrochloric acid, and then add cyanamide.
Add 520 mg (12.36 mmol) and react at 70°C.
After reacting for 10 hours while adding 1N hydrochloric acid to maintain the pH at 4 to 5 during the reaction, the solvent was distilled off under reduced pressure. The residue was mixed with 50 ml of ethyl acetate and 10 ml of ethanol.
ml of mixed solution, 5% sodium carbonate aqueous solution,
Wash sequentially with 0.5N hydrochloric acid and saturated saline. The organic layer is dried over anhydrous sodium sulfate, and after removing the desiccant, it is concentrated under reduced pressure. The resulting residue was coated with silica gel 60
(manufactured by Merck & Co., Ltd.) was applied to a column packed with 8 ml, developed with a mixture of chloroform-methanol (5:1 v/v), and fractions containing the target product were collected and concentrated under reduced pressure to produce 136 mg of pale yellow oil (yield 66.7%). ) is obtained.

NMR(CDCl3) δ=1.1〜2.8(b,12H),1.4(s,18H),2.8〜
3.5(b,8H),3.5〜4.2(b,2H),4.7〜8.4
(b,8H),7.13(bs,4H), IR(KBr) ν(cm-1)=3320,2975,2930,1670,1535,
1515,1480,1450,1420,1365,1280,
1250,1170. TLC(クロロホルム:メタノール=5:1v/
v) Rf=0.2. ニ 10−{N−〔4−(4−Gu−Ph)ブタノイル〕
Gly}−1,5,10−TAD3塩酸塩 10−{N−〔4−(4−Gu−Ph)ブタノイル〕
Gly}−1,5−di−Z−1,5,10−TAD塩酸
塩0.55g(0.86mmol)に氷冷下トリフルオロ酢
酸2mlを加えて溶かし、室温で2時間反応させ
る。反応液を減圧で濃縮し、得られた油状物を実
施例1−ニ)と同様に処理することにより、目的
物195mg(収率41.1%)が得られる。
NMR ( CDCl3 ) δ=1.1~2.8 (b, 12H), 1.4 (s, 18H), 2.8~
3.5 (b, 8H), 3.5-4.2 (b, 2H), 4.7-8.4
(b, 8H), 7.13 (bs, 4H), IR (KBr) ν (cm -1 ) = 3320, 2975, 2930, 1670, 1535,
1515, 1480, 1450, 1420, 1365, 1280,
1250, 1170. TLC (Chloroform: Methanol = 5:1v/
v) Rf=0.2. d 10-{N-[4-(4-Gu-Ph)butanoyl]
Gly}-1,5,10-TAD3 hydrochloride 10-{N-[4-(4-Gu-Ph)butanoyl]
Gly}-1,5-di-Z-1,5,10-TAD hydrochloride (0.55 g (0.86 mmol)) was dissolved by adding 2 ml of trifluoroacetic acid under ice cooling, and the mixture was allowed to react at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the resulting oil was treated in the same manner as in Example 1-d) to obtain 195 mg (yield: 41.1%) of the desired product.

Mp 153−155℃ ここで得られた結晶は、実施例1のニ)で得ら
れた標品とNMRスペクトルおよびIRスペクトル
等においてよく一致した。
Mp 153-155°C The crystal obtained here was in good agreement with the specimen obtained in Example 1 d) in terms of NMR spectrum, IR spectrum, etc.

実施例 3 イ 10−{N−〔4−(4−Boc−A−Ph)ブタノ
イル〕−O−Bzl−L−Ser}−1,5−di−Z
−1,5,10−TAD 白色結晶の4−(4−Boc−A−Ph)酪酸1.12
g(4.0mmol)をテトラヒドロフラン20mlに溶か
し、氷冷下DCC0.99g(4.8mmol)とN−ヒドロ
キシコハク酸イミド0.55g(4.8mmol)を加え、
室温で一夜反応させる。析出したN,N′−ジシ
クロヘキシル尿素を別し液はそのまま次の反
応に使用する淡黄色油状の10−(0−Bzl−L−
Ser)−1,5−di−Z−1,5,10−TAD4.67
g(3.94mmol)をテトラヒドロフラン30mlに溶
かし、氷冷下トリエチルアミン0.49g
(4.8mmol)を加え、次いで上に述べた4−(4−
Boc−A−Ph)酪酸N−ヒドロキシコハク酸イ
ミドエステルのテトラヒドロフラン溶液を加え、
室温で一夜反応させる。反応液にN,N−ジエチ
ル−1,3−プロパンジアミン1mlを加え、室温
で1時間撹拌後、反応液を減圧濃縮する。油状の
残渣を酢酸エチル200mlに溶かし、5%リン酸、
5%炭酸ナトリウム水溶液、飽和食塩水で順次洗
浄する。有機層を無水硫酸ナトリウムで乾燥し、
乾燥剤を別後液を減圧濃縮すると、淡黄色油
状の目的物2.92g(収率86.9%)が得られる。
Example 3 A 10-{N-[4-(4-Boc-A-Ph)butanoyl]-O-Bzl-L-Ser}-1,5-di-Z
-1,5,10-TAD White crystalline 4-(4-Boc-A-Ph)butyric acid 1.12
Dissolve g (4.0 mmol) in 20 ml of tetrahydrofuran, add 0.99 g (4.8 mmol) of DCC and 0.55 g (4.8 mmol) of N-hydroxysuccinimide under ice cooling,
Incubate overnight at room temperature. The precipitated N,N'-dicyclohexylurea was separated and the liquid was left as a pale yellow oily 10-(0-Bzl-L-
Ser) -1,5-di-Z-1,5,10-TAD4.67
Dissolve g (3.94 mmol) in 30 ml of tetrahydrofuran and add 0.49 g of triethylamine under ice cooling.
(4.8 mmol) and then 4-(4-
Boc-A-Ph) Add a tetrahydrofuran solution of butyric acid N-hydroxysuccinimide ester,
Incubate overnight at room temperature. 1 ml of N,N-diethyl-1,3-propanediamine was added to the reaction solution, and after stirring at room temperature for 1 hour, the reaction solution was concentrated under reduced pressure. Dissolve the oily residue in 200 ml of ethyl acetate, add 5% phosphoric acid,
Wash sequentially with 5% aqueous sodium carbonate solution and saturated saline. The organic layer was dried with anhydrous sodium sulfate,
After removing the drying agent, the liquid was concentrated under reduced pressure to obtain 2.92 g (yield: 86.9%) of the desired product as a pale yellow oil.

NMR(CDCl3) δ=1.1〜2.3(b,10H),1.47(s,9H),2.3〜
2.8(b,2H),2.8〜3.5(b,8H),3.5〜3.9
(b,2H),4.3〜4.7(b,H),4.47(s,
2H),5.04(s,4H),6.3〜7.4(b,4H),
6.8〜7.4(m,4H),7.27(s,15H). IR(KBr) ν(cm-1)=3330,2950,1700,1650,1505,
1475,1450,1420,1365,1315,1245,
1160,1050,1025,735. TLC(クロロホルム:メタノール=10:1v/
v) Rf=0.47 ロ 10−{N−〔4−(4−A−Ph)ブタノイル〕
−O−Bzl−L−Ser}−1,5−di−Z−1,
5,10−TAD 10−{N−〔4−(4−Boc−A−Ph)ブタノイ
ル〕−O−Bzl−L−Ser}−1,5−di−Z−1,
5,10−TAD2.85g(3.34mmol)に氷冷下トリ
フルオロ酢酸6mlを加えて溶かし室温で1時間反
応させる。反応液を減圧で濃縮し、得られた油状
物を酢酸150mlに溶かし、5%炭酸ナトリウム水
溶液、飽和食塩水で順次洗浄し、有機層を無水硫
酸ナトリウムで乾燥する。乾燥剤を別後液を
減圧濃縮すると、淡黄色油状物2.5gが得られる。
NMR ( CDCl3 ) δ=1.1~2.3 (b, 10H), 1.47 (s, 9H), 2.3~
2.8 (b, 2H), 2.8~3.5 (b, 8H), 3.5~3.9
(b, 2H), 4.3-4.7 (b, H), 4.47 (s,
2H), 5.04 (s, 4H), 6.3~7.4 (b, 4H),
6.8-7.4 (m, 4H), 7.27 (s, 15H). IR (KBr) ν (cm -1 ) = 3330, 2950, 1700, 1650, 1505,
1475, 1450, 1420, 1365, 1315, 1245,
1160, 1050, 1025, 735. TLC (Chloroform: Methanol = 10:1v/
v) Rf=0.47 b 10-{N-[4-(4-A-Ph)butanoyl]
-O-Bzl-L-Ser}-1,5-di-Z-1,
5,10-TAD 10-{N-[4-(4-Boc-A-Ph)butanoyl]-O-Bzl-L-Ser}-1,5-di-Z-1,
Add 6 ml of trifluoroacetic acid under ice cooling to 2.85 g (3.34 mmol) of 5,10-TAD to dissolve and react at room temperature for 1 hour. The reaction solution is concentrated under reduced pressure, and the resulting oil is dissolved in 150 ml of acetic acid, washed successively with a 5% aqueous sodium carbonate solution and saturated brine, and the organic layer is dried over anhydrous sodium sulfate. After removing the drying agent, the liquid was concentrated under reduced pressure to obtain 2.5 g of a pale yellow oil.

これをシリカゲル(ワコーゲルC−200 )90
mlを充填したカラムに付し、トルエン−酢酸エチ
ル(1:1v/v)の混液で展開し、目的物を含
むフラクシヨンを集め、減圧で濃縮すると淡黄色
油状の目的物2.1g(収率71.2%)が得られる。
Add this to 90% of silica gel (Wakogel C-200)
ml and developed with a mixture of toluene and ethyl acetate (1:1 v/v). Fractions containing the target product were collected and concentrated under reduced pressure to give 2.1 g of the target product as a pale yellow oil (yield 71.2 %) is obtained.

NMR(CDCl3) δ=1.1〜2.3(b,10H),2.3〜2.7(b,2H),
2.7〜4.0(b,12H),4.2〜4.8(b,H),4.47
(s,2H),4.8〜7.9(b,3H),5.07(s,
4H),6.53(d,2H),J=8Hz),6.90(d,
2H,J=8Hz),7.3(s,15H). IR(KBr) ν(cm-1)=3330,2950,2880,1685,1650,
1520,1475,1455,1425,1365,1250,
1215,1145,1030. TLC(クロロホルム:メタノール=10:1v/
v) Rf=0.36. ハ 10−{N−〔4−(4−Gu−Ph)ブタノイル〕
−O−Bzl−L−Ser}−1,5−di−Z−1,
5,10−TAD塩酸塩 油状の10−{N−〔4−(4−A−Ph)ブタノイ
ル〕−O−Bzl−L−Ser}−1,5−di−Z−1,
5,10−TAD100mg(0.13mmol)をテトラヒド
ロフラン2mlに溶かし、1−アミジノ−3,5−
ジメチルピラゾール硝酸塩40mg(0.2mmol)と
N,N−ジイソプロピルエチルアミン25.8mg
(0.2mmol)を加え、還流下で48時間反応させる。
反応液を減圧濃縮し、得られた残渣に酢酸エチル
30mlとエタノール6mlを加えて溶かし、5%炭酸
ナトリウム水溶液1規定塩酸、飽和食塩水で順次
洗浄後、有機層を無水硫酸ナトリウムで乾燥し、
減圧濃縮する。得られた残渣をシリカゲル60
(メルク社製)4mlを充填したカラムに付し、ク
ロロホルム−メタノール−17%アンモニア水
(6:1.5:0.25v/v)の混液で展開し、目的物
を含むフラクシヨンを集め、減圧濃縮すると淡黄
色油状の目的物45mg(収率42.4%)が得られる。
NMR ( CDCl3 ) δ=1.1~2.3 (b, 10H), 2.3~2.7 (b, 2H),
2.7~4.0 (b, 12H), 4.2~4.8 (b, H), 4.47
(s, 2H), 4.8-7.9 (b, 3H), 5.07 (s,
4H), 6.53 (d, 2H), J=8Hz), 6.90 (d,
2H, J=8Hz), 7.3(s, 15H). IR (KBr) ν (cm -1 ) = 3330, 2950, 2880, 1685, 1650,
1520,1475,1455,1425,1365,1250,
1215, 1145, 1030. TLC (Chloroform: Methanol = 10:1v/
v) Rf=0.36. C 10-{N-[4-(4-Gu-Ph)butanoyl]
-O-Bzl-L-Ser}-1,5-di-Z-1,
5,10-TAD hydrochloride oily 10-{N-[4-(4-A-Ph)butanoyl]-O-Bzl-L-Ser}-1,5-di-Z-1,
Dissolve 100 mg (0.13 mmol) of 5,10-TAD in 2 ml of tetrahydrofuran, and dissolve 1-amidino-3,5-
Dimethylpyrazole nitrate 40mg (0.2mmol) and N,N-diisopropylethylamine 25.8mg
(0.2 mmol) and react under reflux for 48 hours.
The reaction solution was concentrated under reduced pressure, and the resulting residue was added with ethyl acetate.
Add 30 ml and 6 ml of ethanol to dissolve, wash sequentially with 5% aqueous sodium carbonate solution, 1N hydrochloric acid, and saturated saline, and dry the organic layer over anhydrous sodium sulfate.
Concentrate under reduced pressure. The resulting residue was coated with silica gel 60
(Manufactured by Merck & Co., Ltd.) It was attached to a column packed with 4 ml and developed with a mixture of chloroform, methanol and 17% aqueous ammonia (6:1.5:0.25v/v), and the fractions containing the target product were collected and concentrated under reduced pressure. 45 mg (yield 42.4%) of the target product was obtained as a yellow oil.

NMR(CDCl3) δ=1.1〜2.8(b,12H),2.8〜3.4(b,8H),
3.4〜4.0(b,2H),4.2〜4.7(b,H),4.43
(s,2H),4.8〜8.8(b,8H),5.03(s,
4H),7.05(bs,4H),7.3(s,15H). IR(KBr) ν(cm-1)=3305,2930,1670,1650,1535,
1515,1450,1420,1260,1215. TLC(クロロホルム:メタノール:17%アン
モニア水=16:1.5:0.25v/v) Rf=0.28. ニ 10−{N−〔4−(4−Gu−Ph)ブタノイル〕
−L−Ser}−1.5,10−TAD3塩酸塩 10−{N−〔4−(4−Gu−Ph)ブタノイル〕−
O−Bzl−L−Ser}−1,5−di−Z−1.5,10−
TAD塩酸塩0.5g(0.6mmol)をメタノール20ml
および酢酸10mlの混液に溶かし、パラジウム黒50
mgを加えて50℃に加温し、常圧で6時間接触還元
を行う。反応後触媒を別し、液を減圧濃縮す
ると油状物0.35gが得られる。以後実施例1−
ニ)と同様に処理することにより、目的物0.14g
(収率42.8%)が得られる。
NMR ( CDCl3 ) δ=1.1~2.8 (b, 12H), 2.8~3.4 (b, 8H),
3.4-4.0 (b, 2H), 4.2-4.7 (b, H), 4.43
(s, 2H), 4.8~8.8 (b, 8H), 5.03 (s,
4H), 7.05 (bs, 4H), 7.3 (s, 15H). IR (KBr) ν (cm -1 ) = 3305, 2930, 1670, 1650, 1535,
1515, 1450, 1420, 1260, 1215. TLC (chloroform: methanol: 17% ammonia water = 16: 1.5: 0.25 v/v) Rf = 0.28. butanoyl]
-L-Ser}-1.5,10-TAD3 hydrochloride 10-{N-[4-(4-Gu-Ph)butanoyl]-
O-Bzl-L-Ser}-1,5-di-Z-1.5,10-
TAD hydrochloride 0.5g (0.6mmol) in methanol 20ml
Palladium black 50
mg was added, heated to 50°C, and subjected to catalytic reduction at normal pressure for 6 hours. After the reaction, the catalyst was separated and the liquid was concentrated under reduced pressure to obtain 0.35 g of an oily substance. Hereinafter, Example 1-
By processing in the same manner as d), 0.14g of the target material
(yield 42.8%).

Mp 141〜144℃ NMR(DMSO−d6) δ=1.1〜2.5(b,12H),2.5〜3.4(b,8H),
3.4〜3.8(bd,3H),4.0〜4.5(b,H),6.9〜
7.5(m,4H),7.1〜7.7(b,4H),7.7〜8.8
(b,5H),8.8〜9.7(b,2H),10.13(bs,
H). IR(KBr) ν(cm-1)=3310,2950,1645,1570,1535,
1510,1450,1250,1155,1060. TLC(n−プロパノール:ピリジン:水:酢
酸=6:4:3:2v/v) Rf=0.34. 〔α〕19.5 D−13.8゜(C=1.17,H2O). 実施例 4 10−〔N−(6−(4−Gu−Ph)ヘキサノイル)
−L−Ser〕−1,5,10−TAD・3塩酸塩 (イ) 10−〔N−(6−(4−Boc−A−Ph)ヘキサ
ノイル)−O−Bzl−L−Ser〕−1,5−di−
Z−1,5,10−TAD 6−(4−Boc−A−Ph)ヘキサン酸1.50g
(4.88mmol)をテトラヒドロフラン25mlに溶解
し、氷冷撹拌下DCC1.23g(5.96mmol)を加え、
さらにN−ハイドロキシスクシンイミド0.680g
(5.91mmol)を加える。添加後室温にもどし5時
間撹拌反応し、析出した結果を別し、液に氷
冷撹拌下10−(0−Bzl−L−Ser)−1,5−di
−Z−1,5,10−TAD3.53g(5.98mmol)を
加える。次いでトリエチルアミン0.83mlを添加
し、室温にもどして一夜撹拌反応後、反応液を減
圧濃縮する。得られた残渣を酢酸エチル500mlに
溶解し、5%リン酸水溶液、5%炭酸ナトリウム
水溶液、蒸留水で順次洗浄する。酢酸エチル層を
無水硫酸ナトリウムで乾燥し、減圧濃縮にて溶媒
を留去すると油状の目的物4.01g(収率93.4%)
が得られる。
Mp 141-144℃ NMR (DMSO- d6 ) δ=1.1-2.5 (b, 12H), 2.5-3.4 (b, 8H),
3.4~3.8 (bd, 3H), 4.0~4.5 (b, H), 6.9~
7.5 (m, 4H), 7.1~7.7 (b, 4H), 7.7~8.8
(b, 5H), 8.8-9.7 (b, 2H), 10.13 (bs,
H). IR (KBr) ν (cm -1 ) = 3310, 2950, 1645, 1570, 1535,
1510, 1450, 1250, 1155, 1060. TLC (n-propanol: pyridine: water: acetic acid = 6:4:3:2 v/v) Rf = 0.34. [α] 19.5 D -13.8° (C = 1.17, H 2 O). Example 4 10-[N-(6-(4-Gu-Ph)hexanoyl)
-L-Ser]-1,5,10-TAD 3-hydrochloride (a) 10-[N-(6-(4-Boc-A-Ph)hexanoyl)-O-Bzl-L-Ser]-1 ,5-di-
Z-1,5,10-TAD 6-(4-Boc-A-Ph)hexanoic acid 1.50g
(4.88 mmol) was dissolved in 25 ml of tetrahydrofuran, and 1.23 g (5.96 mmol) of DCC was added while stirring on ice.
Additionally, 0.680g of N-hydroxysuccinimide
(5.91 mmol) is added. After the addition, the temperature was returned to room temperature, the reaction was stirred for 5 hours, the precipitated result was separated, and the liquid was added with 10-(0-Bzl-L-Ser)-1,5-di under ice-cooling and stirring.
-Z- Add 3.53 g (5.98 mmol) of 1,5,10-TAD. Next, 0.83 ml of triethylamine was added, the mixture was returned to room temperature, and the reaction mixture was stirred overnight, after which the reaction solution was concentrated under reduced pressure. The resulting residue was dissolved in 500 ml of ethyl acetate and washed successively with a 5% aqueous phosphoric acid solution, a 5% aqueous sodium carbonate solution, and distilled water. The ethyl acetate layer was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to give 4.01 g of the target product as an oil (yield 93.4%).
is obtained.

NMR(CDCl3) δ=1.10〜1.95(b,12H),1.50(s,9H),
1.95〜2.35(b,2H),2.35〜2.75(b,2H),
2.95〜3.55(b,8H),3.55〜4.00(m,2H),
4.30〜4.80(b,1H),4.52(s,2H),5.10
(s,4H),5.30〜6.90(b,4H),6.90〜7.40
(m,4H),7.28(s,5H),7.37(s,10H). IR(KBr) ν(cm-1)=3310,2980,2860,1690,1685,
1645,1520,1475,1450,1420,1365,
1310,1240,1155,735,695. TLC(クロロホルム:メタノール=20:1v/
v) Rf=0.55 (ロ) 10−〔N−(6−(4−A−Ph)ヘキサノイ
ル)−O−Bzl−L−Ser〕−1,5−di−Z−
1,5,10−TAD 上記(イ)で得られた10−〔N−(6−(4−Boc−
A−Ph)ヘキサノイル)−O−Bzl−L−Ser〕−
1,5−di−Z−1,5,10−TAD2.58g
(2.93mmol)を氷冷下、トリフルオロ酢酸20mlを
加えてとかす。次いで室温で1時間撹拌反応す
る。反応液を減圧濃縮し、得られた残渣を酢酸エ
チル約300mlに溶解し、5%炭酸ナトリウム水溶
液、蒸留水で順次洗浄する。酢酸エチル層を無水
硫酸ナトリウムで乾燥し、減圧濃縮すると、油状
の目的物2.52g(収率定量的)が得られる。
NMR ( CDCl3 ) δ=1.10-1.95 (b, 12H), 1.50 (s, 9H),
1.95~2.35 (b, 2H), 2.35~2.75 (b, 2H),
2.95~3.55 (b, 8H), 3.55~4.00 (m, 2H),
4.30-4.80 (b, 1H), 4.52 (s, 2H), 5.10
(s, 4H), 5.30~6.90 (b, 4H), 6.90~7.40
(m, 4H), 7.28 (s, 5H), 7.37 (s, 10H). IR (KBr) ν (cm -1 ) = 3310, 2980, 2860, 1690, 1685,
1645, 1520, 1475, 1450, 1420, 1365,
1310, 1240, 1155, 735, 695. TLC (chloroform:methanol = 20:1v/
v) Rf=0.55 (b) 10-[N-(6-(4-A-Ph)hexanoyl)-O-Bzl-L-Ser]-1,5-di-Z-
1,5,10-TAD 10-[N-(6-(4-Boc-
A-Ph)hexanoyl)-O-Bzl-L-Ser]-
1,5-di-Z-1,5,10-TAD2.58g
(2.93 mmol) under ice cooling, add 20 ml of trifluoroacetic acid and dissolve. Then, the mixture is stirred and reacted at room temperature for 1 hour. The reaction solution is concentrated under reduced pressure, and the resulting residue is dissolved in about 300 ml of ethyl acetate, and washed successively with a 5% aqueous sodium carbonate solution and distilled water. The ethyl acetate layer is dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain 2.52 g (quantitative yield) of the target product as an oil.

NMR(CDCl3) δ=1.00〜1.95(b,14H),1.95〜2.70(bm,
4H),2.80〜4.00(bm,12H),4.25〜4.80
(b,1H),4.55(s,2H),5.10(s,4H),
6.00〜7.30(b,3H),6.58(b,2H,J=8.0
Hz),6.95(d,2H,J=8.0Hz),7.33(s,
15H). IR(Neat) ν(cm-1)=3330,2940,2860,1685,1650,
1520,1475,1455,1430,1365,1255,
1230,1150,1100,755,700. TLC(クロロホルム:メタノール=20:1v/
v) Rf=0.46 (ハ) 10−〔N−(6−(4−Gu−Ph)ヘキサノイ
ル)−O−Bzl−L−Ser〕−1,5−di−Z−
1,5,10−TAD塩酸塩 上記(ロ)で得られた10−〔N−(6−(4−A−
Ph)ヘキサノイル)−O−Bzl−L−Ser〕−1,
5−di−Z−1,5,10−TAD1.23g
(1.51mmol)の5mlエタノール溶液に0.1規定塩
酸15.1mlを加え、次いで減圧濃縮にて溶媒を留去
する。得られた塩酸塩を5mlエタノールに溶解
し、シアナミド1.28g(30mmol)を加え、80℃
で撹拌反応させる。途中PHを4〜5に保つ為に塩
酸を添加しながら8時間反応させた後、減圧濃縮
にて溶媒を留去する。残渣を酢酸エチル200mlと
エタノール40mlの混合液に溶解し、5%炭酸ナト
リウム水溶液、1規定塩酸、飽和食塩水で順次洗
浄する。有機層を無水硫酸ナトリウムで乾燥し、
減圧濃縮することにより粗目的物1.38gを得る。
NMR ( CDCl3 ) δ=1.00~1.95 (b, 14H), 1.95~2.70 (bm,
4H), 2.80~4.00 (bm, 12H), 4.25~4.80
(b, 1H), 4.55 (s, 2H), 5.10 (s, 4H),
6.00~7.30 (b, 3H), 6.58 (b, 2H, J=8.0
Hz), 6.95 (d, 2H, J=8.0Hz), 7.33 (s,
15H). IR (Neat) ν (cm -1 ) = 3330, 2940, 2860, 1685, 1650,
1520, 1475, 1455, 1430, 1365, 1255,
1230, 1150, 1100, 755, 700. TLC (chloroform:methanol = 20:1v/
v) Rf=0.46 (c) 10-[N-(6-(4-Gu-Ph)hexanoyl)-O-Bzl-L-Ser]-1,5-di-Z-
1,5,10-TAD hydrochloride 10-[N-(6-(4-A-) obtained in (b) above
Ph)hexanoyl)-O-Bzl-L-Ser]-1,
5-di-Z-1,5,10-TAD1.23g
(1.51 mmol) in 5 ml of ethanol was added 15.1 ml of 0.1N hydrochloric acid, and then the solvent was distilled off under reduced pressure. The obtained hydrochloride was dissolved in 5 ml of ethanol, 1.28 g (30 mmol) of cyanamide was added, and the mixture was heated at 80°C.
Stir to react. After reacting for 8 hours while adding hydrochloric acid to maintain the pH at 4 to 5 during the reaction, the solvent was distilled off under reduced pressure. Dissolve the residue in a mixture of 200 ml of ethyl acetate and 40 ml of ethanol, and wash successively with 5% aqueous sodium carbonate, 1N hydrochloric acid, and saturated brine. The organic layer was dried with anhydrous sodium sulfate,
By concentrating under reduced pressure, 1.38 g of the crude target product was obtained.

得られた粗目的物のうち158mgを分取用TLC
(Merck社製、展開系:クロロホルム:メタノー
ル:17%NH3=6:1.5:0.25v/v)を用いて精
製すると目的物を102mg(収率64.8%)が得られ
る。
158mg of the crude target product obtained was subjected to preparative TLC.
(manufactured by Merck, developing system: chloroform:methanol:17% NH 3 =6:1.5:0.25v/v) to obtain 102 mg (yield: 64.8%) of the target product.

NMR(CDCl3) δ=0.80〜1.95(b,14H),1.95〜2.30(b,
2H),2.30〜2.85(b,2H),2.85〜3.45(b,
8H),3.45〜4.00(bm,2H),4.30〜4.80(b,
1H),4.67(s,2H),5.05(s,4H),5.60〜
7.50(b,8H),7.05(bs,4H),7.25(s,
5H),7.28(s,10H). IR(KBr) ν(cm-1)=3320,2940,1670,1650,1540,
1515,1475,1450,1425,1255,1210,740,
700. TLC(クロロホルム:メタノール:17%アンモ
ニア水=6:1.5:0.25v/v) Rf=0.25 (ニ) 10−〔N−(6−(4−Gu−Ph)ヘキサノイ
ル)−L−Ser〕−1,5,10−TAD・3塩酸塩 上記(ハ)で得られた粗10−〔N−(6−(4−Gu−
Ph)ヘキサノイル)−O−Bzl−L−Ser〕−1,
5−di−Z−1,5,10−TAD1.20g
(1.31mmol)を酢酸15mlとエタノール5mlの混合
液にとかし、5%パラジウム炭素0.2gを加えて
50℃に加温し、常圧で8時間接触還元を行う。反
応後触媒を別し、液を減圧で濃縮すると油状
物1.08gが得られる。この油状物を蒸留水5mlに
溶解し、CM−セフアデツクス C−25(Na+
200mlを充填したカラムに付し、蒸留水1.0と
1.5M塩化ナトリウム水溶液1.0との間のグラジ
エント溶出法で溶出し、目的物を含むフラクシヨ
ンを集め、減圧で乾固し、乾固物にメタノールを
加えて不溶の塩化ナトリウムを別する。この操
作を2回繰り返す。残存する少量の塩化ナトリウ
ムを除去するために得られた残渣をメタノール5
mlに溶かし、セフアデツクス LH−20 100mlを
充填したカラムに付し、メタノールで溶出し、目
的物を含むフラクシヨンを集め、減圧で濃縮す
る。さらに少量の不純物を除去するために得られ
た白色固体を蒸留水3mgに溶かし、三菱化成HP
−20 50mlを充填したカラムにかけ、蒸留水で溶
出し、目的物を含むフラクシヨンを集め、減圧で
濃縮する。得られた残渣をエタノールより再結晶
し、取することにより白色粉末状の目的物0.51
g(収率63.9%)が得られる。
NMR ( CDCl3 ) δ=0.80~1.95 (b, 14H), 1.95~2.30 (b,
2H), 2.30-2.85 (b, 2H), 2.85-3.45 (b,
8H), 3.45-4.00 (bm, 2H), 4.30-4.80 (b,
1H), 4.67 (s, 2H), 5.05 (s, 4H), 5.60~
7.50 (b, 8H), 7.05 (bs, 4H), 7.25 (s,
5H), 7.28 (s, 10H). IR (KBr) ν (cm -1 ) = 3320, 2940, 1670, 1650, 1540,
1515, 1475, 1450, 1425, 1255, 1210, 740,
700. TLC (chloroform:methanol:17% ammonia water = 6:1.5:0.25v/v) Rf=0.25 (d) 10-[N-(6-(4-Gu-Ph)hexanoyl)-L-Ser] -1,5,10-TAD・trihydrochloride Crude 10-[N-(6-(4-Gu-) obtained in (c) above
Ph)hexanoyl)-O-Bzl-L-Ser]-1,
5-di-Z-1,5,10-TAD1.20g
(1.31 mmol) was dissolved in a mixture of 15 ml of acetic acid and 5 ml of ethanol, and 0.2 g of 5% palladium on carbon was added.
Heat to 50°C and perform catalytic reduction at normal pressure for 8 hours. After the reaction, the catalyst was separated and the liquid was concentrated under reduced pressure to obtain 1.08 g of an oil. Dissolve this oil in 5 ml of distilled water and add CM-Sephadex C-25 (Na + ).
Add to a column filled with 200ml and add 1.0ml of distilled water.
Elute using a gradient elution method between 1.0 and 1.5M aqueous sodium chloride solution, collect fractions containing the target product, dry under reduced pressure, and add methanol to the dried product to separate insoluble sodium chloride. Repeat this operation twice. The resulting residue was diluted with methanol 5 ml to remove the remaining small amount of sodium chloride.
ml, applied to a column packed with 100 ml of Sephadex LH-20, eluted with methanol, collected fractions containing the target product, and concentrated under reduced pressure. To further remove a small amount of impurities, the white solid obtained was dissolved in 3 mg of distilled water and Mitsubishi Kasei HP
Apply to a column packed with 50 ml of −20, elute with distilled water, collect fractions containing the target product, and concentrate under reduced pressure. The obtained residue was recrystallized from ethanol and collected to obtain the desired product as a white powder.
g (yield 63.9%).

Mp 159.5−161.5℃ NMR(DMSO−d6) δ=1.00〜1.90(b,12H),1.90〜2.38(b,
4H),2.57〜3.22(b,8H),3.22〜3.85(b,
2H),3.85〜4.55(b,1H),4.55〜5.38(b,
1H),6.95〜7.40(m,4H),7.40〜7.72(n,
3H),7.72〜8.15(b,2H),8.15〜9.32(b,
4H),9.32〜10.53(b,1H). IR(KBr) ν(cm-1)=3280,2930,2775,1640,1555,
1510,1450,1295,1245,1060. TLC(プロパノール:ピリジン:水:酢酸=
6:4:3:2v/v) Rf=0.43 〔α〕20.5 D−13.7゜(C=1.28,H2O) 参考例 1 (1) 10−(N,N−Pht−Gly)−1,5−di−Z
−1,5,10−TAD 1,5−di−Z−1,5,10−TAD12.4g
(30.0mmol)をテトラヒドロフラン200mlに溶か
し、氷冷下トリエチルアミン4.90ml(35.0mmol)
を加え、さらにフタリルグリシンとN−ヒドロキ
シコハク酸イミドとのエステル10.6g
(35.0mmol)を加え、室温で一夜反応させる。
Mp 159.5−161.5℃ NMR (DMSO−d 6 ) δ=1.00–1.90 (b, 12H), 1.90–2.38 (b,
4H), 2.57-3.22 (b, 8H), 3.22-3.85 (b,
2H), 3.85-4.55 (b, 1H), 4.55-5.38 (b,
1H), 6.95-7.40 (m, 4H), 7.40-7.72 (n,
3H), 7.72-8.15 (b, 2H), 8.15-9.32 (b,
4H), 9.32-10.53 (b, 1H). IR (KBr) ν (cm -1 ) = 3280, 2930, 2775, 1640, 1555,
1510, 1450, 1295, 1245, 1060. TLC (propanol: pyridine: water: acetic acid =
6:4:3:2v/v) Rf=0.43 [α] 20.5 D −13.7° (C=1.28, H 2 O) Reference example 1 (1) 10−(N,N−Pht−Gly)−1, 5-di-Z
-1,5,10-TAD 1,5-di-Z-1,5,10-TAD12.4g
(30.0 mmol) in 200 ml of tetrahydrofuran and 4.90 ml (35.0 mmol) of triethylamine under ice cooling.
and 10.6 g of ester of phthalylglycine and N-hydroxysuccinimide.
(35.0 mmol) and react at room temperature overnight.

反応液を減圧乾固し、残渣を酢酸エチル1200ml
に溶かし、酢酸エチル溶液を5%炭酸水素ナトリ
ウム水溶液、0.5規定塩酸、飽和食塩水で順次洗
浄する。酢酸エチル層を無水硫酸ナトリウムで乾
燥後乾燥剤を別し、液を減圧濃縮する。残渣
に酢酸エチルとエチルエーテルを加えて結晶さ
せ、結晶を取、乾燥すると目的物14.6g(収率
81.0%)が得られる。
The reaction solution was dried under reduced pressure, and the residue was dissolved in 1200 ml of ethyl acetate.
The ethyl acetate solution is washed sequentially with 5% aqueous sodium hydrogen carbonate solution, 0.5N hydrochloric acid, and saturated saline. After drying the ethyl acetate layer over anhydrous sodium sulfate, the desiccant was removed and the liquid was concentrated under reduced pressure. The residue was crystallized by adding ethyl acetate and ethyl ether, and the crystals were taken and dried to give 14.6 g of the desired product (yield:
81.0%).

Mp 102−104℃ NMR(DMSO−d6) δ=1.0〜2.2(b,6H),2.7〜3.6(b,8H),
4.20(s,2H),5.01(s,2H),5.03(s,
2H),6.8〜8.4(b,2H),7.30(s,10H),
7.84(s,4H). TLC(クロロホルム:メタノール:酢酸=
95:5:3v/v) Rf=0.4 なお原料の1,5−di−Z−1,5,10−
TADは次のようにして合成される。
Mp 102-104℃ NMR (DMSO- d6 ) δ=1.0~2.2 (b, 6H), 2.7~3.6 (b, 8H),
4.20 (s, 2H), 5.01 (s, 2H), 5.03 (s,
2H), 6.8-8.4 (b, 2H), 7.30 (s, 10H),
7.84 (s, 4H). TLC (chloroform: methanol: acetic acid =
95:5:3v/v) Rf=0.4 Note that the raw material 1,5-di-Z-1,5,10-
TAD is synthesized as follows.

1−(4−アミノブチル)ヘキサヒドロピリミ
ジン55.0g(350mmol)とエトキシカルボニルフ
タルイミド92.0g(420mmol)をジメチルスルホ
キシド580mlに溶解し、ここに氷酢酸42.0g
(700mmol)を添加して室温にて一夜撹拌反応さ
せる。この反応液を真空ポンプを用いて減圧濃縮
する。得られた残渣を蒸留水200mlに溶解し濃塩
酸でPH1.0に調整した後再び減圧濃縮する。残渣
をエタノールから再結晶することにより淡黄色の
10−Pht−1,5,10−TAD2塩酸塩46.9g(収
率38.5%)が得られる。
55.0 g (350 mmol) of 1-(4-aminobutyl)hexahydropyrimidine and 92.0 g (420 mmol) of ethoxycarbonylphthalimide were dissolved in 580 ml of dimethyl sulfoxide, and 42.0 g of glacial acetic acid was added thereto.
(700 mmol) and stir the reaction overnight at room temperature. This reaction solution is concentrated under reduced pressure using a vacuum pump. The resulting residue was dissolved in 200 ml of distilled water, adjusted to pH 1.0 with concentrated hydrochloric acid, and concentrated again under reduced pressure. Recrystallization of the residue from ethanol gives a pale yellow color.
46.9 g (yield 38.5%) of 10-Pht-1,5,10-TAD2 hydrochloride is obtained.

Mp 244−246℃ NMR(D2O) δ=1.5〜2.0(b,4H),2.0〜2.5(m,2H),
2.9〜3.5(b,6H),3.5〜3.9(b,2H),7.76
(s,4H). 得られた10−Pht−1,5,10−TAD2塩酸塩
27.9g(80.0mmol)をクロロホルム300mlに溶解
し、ベンジルS−4,6−ジメチルピリミジン−
2−イル−チオールカルボネート43.9g
(160mmol)及びトリエチルアミン17.8g
(17.6mmol)を添加し、室温にて6時間撹拌反応
させる。反応液を1規定塩酸塩次いで食塩水で順
次洗浄し、無水硫酸マグネシウムで乾燥し、減圧
濃縮すると淡黄色の油状物として、10−Pht−
1,5−di−Z−1,5,10−TAD43.1g(定
量的)が得られる。
Mp 244−246℃ NMR (D 2 O) δ = 1.5 ~ 2.0 (b, 4H), 2.0 ~ 2.5 (m, 2H),
2.9~3.5 (b, 6H), 3.5~3.9 (b, 2H), 7.76
(s, 4H). Obtained 10-Pht-1,5,10-TAD2 hydrochloride
Dissolve 27.9g (80.0mmol) in 300ml of chloroform, and dissolve benzyl S-4,6-dimethylpyrimidine-
2-yl-thiol carbonate 43.9g
(160 mmol) and triethylamine 17.8 g
(17.6 mmol) was added, and the mixture was stirred and reacted at room temperature for 6 hours. The reaction solution was washed with 1N hydrochloride and then with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 10-Pht- as a pale yellow oil.
43.1 g (quantitative) of 1,5-di-Z-1,5,10-TAD are obtained.

NMR(CDCl3) δ=1.3〜2.1(b,6H),1.9〜3.9(m,8H),
5.10(s,4H),7.30〜7.33(s,s,10H),
7.73(m,4H). 10−Pht−1,5−di−Z−1,5,10−
TAD31.3g(57.6mmol)をエタノール600mlに
溶解し、80%抱水ヒドラジン18.2g(291mmol)
を添加し、一夜加熱還流させる。析出した結晶を
別し、液を減圧濃縮する。残渣を酢酸エチル
300mlに溶かし、希塩酸で目的物を抽出し、この
水層を酢酸エチルで洗浄後、炭酸ナトリウムを加
えてPH10に調整する。分離した油状物を酢酸エチ
ル500mlで抽出し、酢酸エチル層を飽和食塩水で
洗浄し、無水硫酸ナトリウムで乾燥した後、減圧
濃縮することにより1,5−di−Z−1,5,10
−TAD20.1g(収率84.8%)が得られる。
NMR ( CDCl3 ) δ=1.3~2.1 (b, 6H), 1.9~3.9 (m, 8H),
5.10 (s, 4H), 7.30~7.33 (s, s, 10H),
7.73 (m, 4H). 10-Pht-1,5-di-Z-1,5,10-
Dissolve 31.3g (57.6mmol) of TAD in 600ml of ethanol and make 18.2g (291mmol) of 80% hydrazine hydrate.
Add and heat to reflux overnight. Separate the precipitated crystals and concentrate the liquid under reduced pressure. The residue was dissolved in ethyl acetate.
Dissolve in 300ml, extract the target substance with diluted hydrochloric acid, wash this aqueous layer with ethyl acetate, and adjust the pH to 10 by adding sodium carbonate. The separated oil was extracted with 500 ml of ethyl acetate, the ethyl acetate layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 1,5-di-Z-1,5,10.
-20.1 g of TAD (yield 84.8%) is obtained.

NMR(CDCl3) δ=1.0〜2.3(b,8H),2.3〜2.9(b,2H),
2.9〜3.5(m,6H),5.05(s,2H),5.07(s,
2H),5.1〜6.1(b,1H),7.30(s,10H) (2) 10−Gly−1,5−di−Z−1,5,10−
TAD 10−(N,N−Pht−Gly)−1,5−di−Z−
1,5,10−TAD14.4g(24.0mmol)にエタノ
ール370mlおよびヒドラジンヒドラート6.00g
(120mmol)を加え、2時間還流させる。反応後
不溶物を別し、液を減圧濃縮する。
NMR ( CDCl3 ) δ=1.0~2.3 (b, 8H), 2.3~2.9 (b, 2H),
2.9-3.5 (m, 6H), 5.05 (s, 2H), 5.07 (s,
2H), 5.1~6.1 (b, 1H), 7.30 (s, 10H) (2) 10−Gly−1,5-di−Z−1,5,10−
TAD 10−(N,N-Pht-Gly)-1,5-di-Z-
1,5,10-TAD 14.4g (24.0mmol), ethanol 370ml and hydrazine hydrate 6.00g
(120 mmol) and reflux for 2 hours. After the reaction, insoluble materials are separated and the liquid is concentrated under reduced pressure.

得られた油状物を酢酸エチル300mlに溶かし、
5%炭酸水素ナトリウム水溶液、蒸留水で順次洗
浄し、酢酸エチル層を無水硫酸ナトリウムで乾燥
する。乾燥剤を別後液を減圧濃縮すると、油
状の目的物12.5g(収率定量的)が得られる。
Dissolve the obtained oil in 300ml of ethyl acetate,
Wash sequentially with 5% aqueous sodium hydrogen carbonate solution and distilled water, and dry the ethyl acetate layer over anhydrous sodium sulfate. After removing the desiccant, the liquid was concentrated under reduced pressure to obtain 12.5 g (quantitative yield) of the target product as an oil.

NMR(CDCl3) δ=0.8〜2.1(b,6H),2.8〜3.5(b,10H),
5.0〜6.1(b,2H),5.06(s,2H),5.10(s,
2H),7.33(s,10H). TLC(クロロホルム:メタノール:酢酸=95:
5:3v/v) Rf=0.1 参考例 2 (1) 10−(N−Boc−O−Bzl−L−Ser−1,5
−di−Z−1,5,10−TAD 1,5−di−Z−1,5,10−TAD4.76g
(11.5mmol)を酢酸エチル50mlに溶かし、氷冷下
トリエチルアミン1.04g(10.3mmol)を加え、
さらにN−Boc−O−Bzl−L−SerとN−ヒドロ
キシコハク酸イミドとのエステル5.87g(約
15mmol)を加え、室温で一夜反応させる。反応
液に酢酸エチル50mlを加え、酢酸エチル溶液を5
%炭酸水素ナトリウム水溶液、0.1規定塩酸、飽
和食塩水で順次洗浄する。酢酸エチル層を無水硫
酸ナトリウムで乾燥後乾燥剤を別し、液を減
圧濃縮すると目的物8.34g(収率定量的)が得ら
れる。
NMR ( CDCl3 ) δ=0.8~2.1 (b, 6H), 2.8~3.5 (b, 10H),
5.0~6.1 (b, 2H), 5.06 (s, 2H), 5.10 (s,
2H), 7.33 (s, 10H). TLC (chloroform: methanol: acetic acid = 95:
5:3v/v) Rf=0.1 Reference example 2 (1) 10-(N-Boc-O-Bzl-L-Ser-1,5
-di-Z-1,5,10-TAD 1,5-di-Z-1,5,10-TAD4.76g
(11.5 mmol) was dissolved in 50 ml of ethyl acetate, and 1.04 g (10.3 mmol) of triethylamine was added under ice cooling.
Furthermore, 5.87 g of ester of N-Boc-O-Bzl-L-Ser and N-hydroxysuccinimide (approx.
15 mmol) and react at room temperature overnight. Add 50 ml of ethyl acetate to the reaction solution, and add 50 ml of ethyl acetate solution.
Wash sequentially with % sodium bicarbonate aqueous solution, 0.1N hydrochloric acid, and saturated saline. After drying the ethyl acetate layer over anhydrous sodium sulfate, the desiccant was removed and the liquid was concentrated under reduced pressure to obtain 8.34 g (quantitative yield) of the desired product.

NMR(CDCl3) δ=0.8〜2.2(b,6H),1.46(s,9H),2.7〜
3.5(b,8H),3.66(m,2H),3.9〜4.4(b,
1H),4.50(s,2H),5.11(s,4H),5.1〜
5.4(b,2H),6.1〜6.8(b,1H),7.33(s,
15H) TLC(クロロホルム:メタノール=9:1v/
v) Rf=0.8 (2) 10−(O−Bzl−L−Ser)−1,5−di−Z
−1,5,10−TAD 10−(N−Boc−O−Bzl−L−Ser)−1,5−
di−Z−1,5,10−TAD8.00g(11.5mmol)
にトリフルオロ酢酸8.0mlを加えて溶かし、室温
で3時間反応させる。反応液を減圧で濃縮し、得
られた油状物を酢酸エチル200mlに溶かし、5%
炭酸水素ナトリウム溶液、蒸留水で順次洗浄し、
酢酸エチル層を無水硫酸ナトリウムで乾燥する。
乾燥剤を別後液を減圧濃縮すると、油状の目
的物6.82g(収率定量的)が得られる。
NMR ( CDCl3 ) δ=0.8~2.2 (b, 6H), 1.46 (s, 9H), 2.7~
3.5 (b, 8H), 3.66 (m, 2H), 3.9~4.4 (b,
1H), 4.50 (s, 2H), 5.11 (s, 4H), 5.1~
5.4 (b, 2H), 6.1-6.8 (b, 1H), 7.33 (s,
15H) TLC (chloroform:methanol = 9:1v/
v) Rf=0.8 (2) 10-(O-Bzl-L-Ser)-1,5-di-Z
-1,5,10-TAD 10-(N-Boc-O-Bzl-L-Ser)-1,5-
di-Z-1,5,10-TAD8.00g (11.5mmol)
Add 8.0 ml of trifluoroacetic acid to dissolve and react at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure, and the resulting oil was dissolved in 200 ml of ethyl acetate to give a concentration of 5%
Wash sequentially with sodium bicarbonate solution and distilled water,
The ethyl acetate layer is dried over anhydrous sodium sulfate.
After removing the drying agent, the liquid was concentrated under reduced pressure to obtain 6.82 g (quantitative yield) of the target product as an oil.

NMR(CDCl3) δ=1.2〜2.0(b,6H),1.74(s,2H),2.8〜
3.5(b,8H),3.64(m,3H),4.51(s,
2H),5.12(s,4H),4.6〜6.0(b,2H),
7.33(s,15H). TLC(クロロホルム:メタノール=9:1v/
v) Rf=0.5 参考例 3 (1) 10−Z−Gly−1,5−di−Boc−1,5,
10−TAD Z−グリシン0.58g(2.77mmol)をテトラヒ
ドロフラン20mlに溶かし、氷冷下DCC0.69g
(3.32mmol)とN−ヒドロキシコハク酸イミド
0.38g(3.32mmol)を加え、室温で6時間反応
させる。析出したN,N′−ジシクロヘキシル尿
素を別し、液に氷冷下1,5−di−Boc−
1,5,10−TAD0.75g(2.17mmol)を加え、
次いでトリエチルアミン0.44g(4.16mmol)を
加えて室温で一夜反応させる。反応液にN,N−
ジエチル−1,3−プロパンジアミン1mlを加
え、室温で1時間撹拌後、反応液を減圧濃縮す
る。油状の残渣を酢酸エチル100mlに溶かし、2.5
%リン酸、5%炭酸ナトリウム水溶液、飽和食塩
水で順次洗浄する。有機層を無水硫酸ナトリウム
で乾燥し、乾燥剤を別後、液を減圧濃縮する
と淡黄色油状の目的物1.05g(収率90.5%)が得
られる。
NMR ( CDCl3 ) δ=1.2~2.0 (b, 6H), 1.74 (s, 2H), 2.8~
3.5 (b, 8H), 3.64 (m, 3H), 4.51 (s,
2H), 5.12 (s, 4H), 4.6-6.0 (b, 2H),
7.33 (s, 15H). TLC (chloroform:methanol=9:1v/
v) Rf=0.5 Reference example 3 (1) 10-Z-Gly-1,5-di-Boc-1,5,
Dissolve 0.58 g (2.77 mmol) of 10-TAD Z-glycine in 20 ml of tetrahydrofuran and add 0.69 g of DCC under ice cooling.
(3.32mmol) and N-hydroxysuccinimide
Add 0.38g (3.32mmol) and react at room temperature for 6 hours. Separate the precipitated N,N'-dicyclohexylurea and add 1,5-di-Boc- to the liquid under ice cooling.
Add 0.75g (2.17mmol) of 1,5,10-TAD,
Then, 0.44 g (4.16 mmol) of triethylamine is added and the mixture is allowed to react overnight at room temperature. N,N- in the reaction solution
1 ml of diethyl-1,3-propanediamine was added, and after stirring at room temperature for 1 hour, the reaction solution was concentrated under reduced pressure. Dissolve the oily residue in 100 ml of ethyl acetate and add 2.5
% phosphoric acid, 5% aqueous sodium carbonate solution, and saturated saline solution. The organic layer is dried over anhydrous sodium sulfate, and after removing the desiccant, the liquid is concentrated under reduced pressure to obtain 1.05 g (yield 90.5%) of the target product as a pale yellow oil.

NMR(CDCl3) δ=1.0〜2.0(b,6H),1.47(s,18H),2.7〜
3.6(b,8H),3.7〜4.0(bd,2H),4.7〜5.4
(b,H),5.1(s,2H),5.6〜6.2(b,H),
6.3〜6.9(b,H),7.33(s,5H). IR(Neat) ν(cm-1)=3330,2970,2930,1680,1520,
1475,1455,1420,1390,1370,1250,
1170,1080,1045,990. TLC(クロロホルム:メタノール=10:1v/
v) Rf=0.47. (2) 10−グリシン−1,5−ジ−tert−ブチルオ
キシカルボニル−1,5,10−トリアザデカン 10−Z−Gly−1,5−di−Boc−1,5,10
−TAD1.05g(1.96mmol)をメタノール30mlに
溶かし、パラジウム黒0.1gを加えて室温、常圧
で6時間接触還元を行う。反応後触媒を別し、
液を減圧濃縮すると淡黄色油状物0.79g(収率
定量的)が得られる。
NMR ( CDCl3 ) δ=1.0~2.0 (b, 6H), 1.47 (s, 18H), 2.7~
3.6 (b, 8H), 3.7~4.0 (bd, 2H), 4.7~5.4
(b, H), 5.1 (s, 2H), 5.6~6.2 (b, H),
6.3-6.9 (b, H), 7.33 (s, 5H). IR (Neat) ν (cm -1 ) = 3330, 2970, 2930, 1680, 1520,
1475, 1455, 1420, 1390, 1370, 1250,
1170, 1080, 1045, 990. TLC (chloroform:methanol = 10:1v/
v) Rf=0.47. (2) 10-Glycine-1,5-di-tert-butyloxycarbonyl-1,5,10-triazadecane 10-Z-Gly-1,5-di-Boc-1,5, Ten
- Dissolve 1.05 g (1.96 mmol) of TAD in 30 ml of methanol, add 0.1 g of palladium black, and perform catalytic reduction at room temperature and normal pressure for 6 hours. After the reaction, separate the catalyst,
The liquid was concentrated under reduced pressure to obtain 0.79 g of a pale yellow oil (yield quantitative).

NMR(CDCl3) δ=1.1〜2.3(b,6H),1.45(s,18H),2.7〜
3.7(b,8H),3.7〜4.6(b,2H),4.6〜9.2
(b,4H). IR(Neat) ν(cm-1)=3330,2975,2930,1670,1420,
1390,1370,1250,1170,1080,1040,890. TLC(クロロホルム:メタノール=3:1v/
v) Rf=0.44. 参考例 4 イ 4−(4−Boc−A−Ph)酪酸 4−(4−A−Ph)酪酸3.76g(21mmol)を
テトラヒドロフラン40mlと水40mlの混液に溶か
し、氷冷下トリエチルアミン3.0g(29.4mmol)
を加え、次いでジ−tert−ブチルジカルボネート
5.5g(25.2mmol)を加え、室温で一夜反応させ
る。
NMR ( CDCl3 ) δ=1.1~2.3 (b, 6H), 1.45 (s, 18H), 2.7~
3.7 (b, 8H), 3.7~4.6 (b, 2H), 4.6~9.2
(b, 4H). IR (Neat) ν (cm -1 ) = 3330, 2975, 2930, 1670, 1420,
1390, 1370, 1250, 1170, 1080, 1040, 890. TLC (chloroform:methanol = 3:1v/
v) Rf=0.44. Reference example 4 A 4-(4-Boc-A-Ph) butyric acid Dissolve 3.76 g (21 mmol) of 4-(4-A-Ph) butyric acid in a mixture of 40 ml of tetrahydrofuran and 40 ml of water, and cool on ice. Lower triethylamine 3.0g (29.4mmol)
and then di-tert-butyl dicarbonate
Add 5.5 g (25.2 mmol) and react overnight at room temperature.

反応液を減圧で濃縮し、得られた残渣を酢酸エ
チル200mlに溶かし、5%リン酸、飽和食塩水で
順次洗浄し、有機層を無水硫酸ナトリウムで乾燥
する。乾燥剤を別後、液を減圧濃縮すると、
淡黄色結晶が得られる。これを石油エーテルで懸
濁させ、別後乾燥すると、白色結晶5.84g(収
率定量的)が得られる。
The reaction solution is concentrated under reduced pressure, and the resulting residue is dissolved in 200 ml of ethyl acetate, washed successively with 5% phosphoric acid and saturated brine, and the organic layer is dried over anhydrous sodium sulfate. After removing the desiccant, the liquid is concentrated under reduced pressure.
Pale yellow crystals are obtained. This is suspended in petroleum ether, separated and dried to obtain 5.84 g of white crystals (quantitative yield).

NMR(CDCl3) δ=1.53(s,9H),1.6〜2.9(m,6H),6.3〜
7.3(b,H),6.8〜7.5(m,4H),11.23(s,
H). IR(KBr) ν(cm-1)=3380,2980,2940,1700,1595,
1525,1415,1365,1310,1235,1160,
1050. TLC(ベンゼン:酢酸エチル:酢酸=3:2:
0.25v/v) Rf=0.57. 参考例 5 イ 4−(4−Z−A−Ph)酪酸 4−(4−A−Ph)酪酸0.7g(3.9mmol)をテ
トラヒドロフラン7mlと水0.5mlの混液に溶かし、
氷冷下トリエチルアミン0.79g(7.8mmol)とベ
ンジル−S−4,6−ジメチルピリジン−2−イ
ル−チオールカルボネート2.1g(7.8mmol)を
加え、室温で一夜反応させる。析出した不溶物を
別し、液を減圧濃縮する。得られた残渣を酢
酸エチル60mlに溶かし、5%リン酸、飽和食塩水
で順次洗浄し、有機層を無水硫酸ナトリウムで乾
燥する。乾燥剤を別後、減圧濃縮すると、淡桃
色結晶が得られる。これをジエチルエーテル・石
油エーテル(1:3v/v)の混液にて再結する
と、白色結晶0.9g(収率73.8%)が得られる。
NMR ( CDCl3 ) δ=1.53 (s, 9H), 1.6~2.9 (m, 6H), 6.3~
7.3 (b, H), 6.8-7.5 (m, 4H), 11.23 (s,
H). IR (KBr) ν (cm -1 ) = 3380, 2980, 2940, 1700, 1595,
1525, 1415, 1365, 1310, 1235, 1160,
1050. TLC (benzene: ethyl acetate: acetic acid = 3:2:
0.25v/v) Rf=0.57. Reference Example 5 A 4-(4-Z-A-Ph) Butyric Acid 0.7 g (3.9 mmol) of 4-(4-A-Ph) Butyric acid was mixed with 7 ml of tetrahydrofuran and 0.5 ml of water. Dissolve in
Under ice cooling, 0.79 g (7.8 mmol) of triethylamine and 2.1 g (7.8 mmol) of benzyl-S-4,6-dimethylpyridin-2-yl-thiol carbonate are added, and the mixture is allowed to react overnight at room temperature. Separate the precipitated insoluble matter, and concentrate the liquid under reduced pressure. The resulting residue was dissolved in 60 ml of ethyl acetate, washed successively with 5% phosphoric acid and saturated brine, and the organic layer was dried over anhydrous sodium sulfate. After removing the desiccant, the mixture is concentrated under reduced pressure to obtain pale pink crystals. When this is reconsolidated with a mixture of diethyl ether and petroleum ether (1:3 v/v), 0.9 g of white crystals (yield 73.8%) are obtained.

NMR(CDCl3) δ=1.7〜2.9(m,6H),5.17(s,2H),6.5〜
7.2(b,H),6.9〜7.5(m,4H),7.33(s,
5H),9.8〜10.6(b,H). IR(KBr) ν(cm-1)=3330,3050,2950,1705,1595,
1535,1420,1320,1245,1070,735. TLC(ベンゼン:酢酸エチル:酢酸=3:2:
0.25v/v) Rf=0.64 参考例 6 (1) 6−フエニルヘキサ−2,4−ジエン酸メチ
ルエステル フエニルアセトアルデヒド11.08g(純度90%、
83mmol)を400mlのトルエンに溶かし、氷冷撹
拌下3−メトキシカルボニル−2−プロピレニリ
デントリフエニルホスホラン29.9g(83mmol)
を加える。30分氷冷で撹拌した後、室温にもど
し、4時間撹拌反応させ、減圧にて溶媒を留去す
る。残渣にエチルエーテル約300mlを加え、析出
する不溶物を別し、減圧濃縮する。得られた油
状物をシリカゲルカラムクロマトグラフイ〔ワコ
ーゲルC−200 、350g、n−ヘキサン−クロロ
ホルム−酢酸エチル(6:1.5:0.3v/v)で展
開〕により分離精製すると、6−フエニルヘキサ
−2,4−ジエン酸メチルエステルのシス、トラ
ンス立体異性体を合わせて12.2g(収率72.9%)
が得られる。
NMR ( CDCl3 ) δ=1.7~2.9 (m, 6H), 5.17 (s, 2H), 6.5~
7.2 (b, H), 6.9-7.5 (m, 4H), 7.33 (s,
5H), 9.8-10.6 (b, H). IR (KBr) ν (cm -1 ) = 3330, 3050, 2950, 1705, 1595,
1535, 1420, 1320, 1245, 1070, 735. TLC (benzene: ethyl acetate: acetic acid = 3:2:
0.25v/v) Rf=0.64 Reference Example 6 (1) 6-Phenylhexa-2,4-dienoic acid methyl ester Phenylacetaldehyde 11.08g (purity 90%,
83 mmol) was dissolved in 400 ml of toluene, and 29.9 g (83 mmol) of 3-methoxycarbonyl-2-propylenylidene triphenylphosphorane was dissolved under ice-cooling and stirring.
Add. After stirring under ice cooling for 30 minutes, the mixture was returned to room temperature, stirred and reacted for 4 hours, and the solvent was distilled off under reduced pressure. Approximately 300 ml of ethyl ether is added to the residue, the precipitated insoluble matter is separated, and the mixture is concentrated under reduced pressure. The obtained oil was separated and purified by silica gel column chromatography [Wako Gel C-200, 350 g, developed with n-hexane-chloroform-ethyl acetate (6:1.5:0.3v/v)] to obtain 6-phenylhex-2. , 12.2 g (yield 72.9%) of cis and trans stereoisomers of 4-dienoic acid methyl ester
is obtained.

NMR(CDCl3) δ=3.60(d,2H,J=8Hz),3.73(s,3H),
5.60〜6.50(m,3H),7.20(bs,5H),7.62
(d,0.62H,J=12.4Hz),7.88(d,0.38H,
J=12.4Hz). TLC(n−ヘキサン:クロロホルム:酢酸エ
チル=6:3:0.5v/v) Rf=0.45,0.49. (2) 6−(4−ニトロフエニル)ヘキサ−2,4
−ジエン酸メチルエステル 前記(1)で得られた6−フエニルヘキサ−2,4
−ジエン酸メチル5.42g(26.8mmol)を寒剤冷
却下硫酸50mlに溶解し、0℃以下で61%硝酸2.10
mlと硫酸8mlの混液を滴下する。滴下後混合液を
1時間0℃以下で撹拌反応し、次いで大量の氷水
中に注ぐ。沈澱物を酢酸エチル600mlで抽出し、
有機層を飽和炭酸水素ナトリウム水溶液及び蒸留
水で順次洗浄後、無水硫酸ナトリウムで乾燥す
る。乾燥剤を別後、液を減圧濃縮し、得られ
た残渣をシリカゲルカラムクロマトグラフイー
〔ワコーゲルC−200 、250g、n−ヘキサン−
クロロホルム−酢酸エチル(6:3:0.5v/v)
で展開〕により分離精製すると、目的物のシス、
トランス混合物を合せて2.25g(収率34.0%)が
得られる。
NMR (CDCl 3 ) δ=3.60 (d, 2H, J=8Hz), 3.73 (s, 3H),
5.60-6.50 (m, 3H), 7.20 (bs, 5H), 7.62
(d, 0.62H, J=12.4Hz), 7.88 (d, 0.38H,
J=12.4Hz). TLC (n-hexane:chloroform:ethyl acetate=6:3:0.5v/v) Rf=0.45, 0.49. (2) 6-(4-nitrophenyl)hex-2,4
-dienoic acid methyl ester 6-phenylhexa-2,4 obtained in (1) above
- Dissolve 5.42 g (26.8 mmol) of methyl dienoate in 50 ml of sulfuric acid under cooling with cryogen, and add 2.10 g of 61% nitric acid at below 0°C.
ml and 8 ml of sulfuric acid was added dropwise. After the addition, the mixture is stirred and reacted at 0° C. or lower for 1 hour, and then poured into a large amount of ice water. The precipitate was extracted with 600ml of ethyl acetate,
The organic layer is washed successively with a saturated aqueous sodium bicarbonate solution and distilled water, and then dried over anhydrous sodium sulfate. After removing the desiccant, the liquid was concentrated under reduced pressure, and the resulting residue was subjected to silica gel column chromatography [Wakogel C-200, 250 g, n-hexane].
Chloroform-ethyl acetate (6:3:0.5v/v)
When separated and purified by
A total of 2.25 g (34.0% yield) of the trans mixture is obtained.

NMR(CDCl3) δ=3.5〜3.9(m,2H),3.73(s,3H),5.67〜
6.80(m,3H),7.06〜7.80(m,1H),7.35
(d,2H,J=8.0Hz),8.15(d,2H,J=
8.0Hz). IR(KBr) ν(cm-1)=3040,2955,1710,1635,1605,
1595,1510,1430,1340,1310,1300,
1245,1200,1150,1130,1105,1000,855,
845,825,745,695. TLC(n−ヘキサン:クロロホルム:酢酸エ
チル=6:3:0.5v/v) Rf=0.33,0.37 (3) 6−(4−A−Ph)ヘキサン酸メチルエステ
ル 前記(2)で得られた6−(4−ニトロフエニル)
ヘキサ−2,4−ジエン酸メチルエステル2.00g
(8.09mmol)をメタノール60mlに溶解し5%パラ
ジウム炭素0.25gを添加し、室温常圧で4時間接
触還元を行う。反応後触媒を別し、液を減圧
濃縮すると淡黄色油状の目的物1.75g(収率97.7
%)が得られる。
NMR ( CDCl3 ) δ=3.5~3.9 (m, 2H), 3.73 (s, 3H), 5.67~
6.80 (m, 3H), 7.06-7.80 (m, 1H), 7.35
(d, 2H, J=8.0Hz), 8.15(d, 2H, J=
8.0Hz). IR (KBr) ν (cm -1 ) = 3040, 2955, 1710, 1635, 1605,
1595, 1510, 1430, 1340, 1310, 1300,
1245, 1200, 1150, 1130, 1105, 1000, 855,
845, 825, 745, 695. TLC (n-hexane: chloroform: ethyl acetate = 6: 3: 0.5 v/v) Rf = 0.33, 0.37 (3) 6-(4-A-Ph) hexanoic acid methyl ester 6-(4-nitrophenyl) obtained in (2)
Hexa-2,4-dienoic acid methyl ester 2.00g
(8.09 mmol) was dissolved in 60 ml of methanol, 0.25 g of 5% palladium on carbon was added, and catalytic reduction was performed at room temperature and normal pressure for 4 hours. After the reaction, the catalyst was separated and the liquid was concentrated under reduced pressure to obtain 1.75 g of the target product as a pale yellow oil (yield: 97.7
%) is obtained.

NMR(CDCl3) δ=1.00〜2.03(b,6H),2.07〜2.73(m,
4H),3.52(s,2H),3.63(s,3H),6.55
(d,2H,J=8.0Hz),6.93(d,2H,J=
8.0Hz). IR(Neat) ν(cm-1)=3380,2940,2855,1730,1620,
1520,1455,1435,1265,1200,1175,825,
750. TLC(トルエン:酢酸エチル=10:1v/v) Rf=0.23 (4) 6−(4−Boc−Ph)ヘキサン酸メチルエス
テル 前記(3)で得られた6−(4−A−Ph)ヘキサン
酸メチルエステル1.70g(7.68mmol)をクロロ
ホルム60mlに溶解し、トリエチルアミン0.93g
(9.22mmol)を添加し、さらにジ−tert−ブチル
−ジカルボネート2.00g(9.16mmol)を加え、
室温で一夜撹拌反応させる。次いでN,N−ジエ
チルプロパンジアミン約1.0mlを加えた後、反応
液を減圧濃縮する。得られた残渣を酢酸エチル約
300mlに溶解し、5%リン酸水溶液、飽和炭酸水
素ナトリウム水溶液、蒸留水で順次洗浄する。酢
酸エチル層を無水硫酸ナトリウムで乾燥後、減圧
濃縮乾固すると、油状の目的物1.97g(収率79.8
%)が得られる。
NMR ( CDCl3 ) δ=1.00~2.03 (b, 6H), 2.07~2.73 (m,
4H), 3.52 (s, 2H), 3.63 (s, 3H), 6.55
(d, 2H, J=8.0Hz), 6.93(d, 2H, J=
8.0Hz). IR (Neat) ν (cm -1 ) = 3380, 2940, 2855, 1730, 1620,
1520, 1455, 1435, 1265, 1200, 1175, 825,
750. TLC (toluene: ethyl acetate = 10:1 v/v) Rf = 0.23 (4) 6-(4-Boc-Ph) hexanoic acid methyl ester 6-(4-A-Ph obtained in (3) above) ) Dissolve 1.70 g (7.68 mmol) of hexanoic acid methyl ester in 60 ml of chloroform, and add 0.93 g of triethylamine.
(9.22 mmol), further added 2.00 g (9.16 mmol) of di-tert-butyl dicarbonate,
Stir the reaction overnight at room temperature. Next, about 1.0 ml of N,N-diethylpropanediamine is added, and the reaction solution is concentrated under reduced pressure. The resulting residue was dissolved in ethyl acetate approx.
Dissolve in 300 ml and wash sequentially with 5% phosphoric acid aqueous solution, saturated sodium bicarbonate aqueous solution, and distilled water. The ethyl acetate layer was dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure to give 1.97 g of the target product as an oil (yield 79.8
%) is obtained.

NMR(CDCl3) δ=1.00〜2.00(b,6H),1.50(s,9H),2.10
〜2.80(m,4H),6.45〜6.85(b,1H),6.90
〜7.40(m,4H). IR(Neat) ν(cm-1)=3350,2980,2940,2860,1725,
1595,1530,1415,1370,1315,1235,
1160,1050. TLC(トルエン:酢酸エチル=10:1v/v) Rf=0.41 (5) 6−(4−Boc−Ph)ヘキサン酸 前記(4)で得られた6−(4−Boc−Ph)ヘキサ
ン酸メチルエステル1.94g(6.04mmol)をメタ
ノール40mlに溶解し、冷却下1規定水酸化ナトリ
ウム15mlを加え、次いで室温にもどして4時間撹
拌反応させる。5%リン酸水溶液を滴下すること
により反応液のPHを1に調整し酢酸エチル200ml
で抽出を行う。有機層を蒸留水で洗浄し、無水硫
酸ナトリウムで乾燥する。乾燥剤を別後、液
を減圧濃縮乾固すると白色固体として目的物1.52
g(収率81.9%)が得られる。
NMR ( CDCl3 ) δ=1.00-2.00 (b, 6H), 1.50 (s, 9H), 2.10
~2.80 (m, 4H), 6.45 ~ 6.85 (b, 1H), 6.90
~7.40 (m, 4H). IR (Neat) ν (cm -1 ) = 3350, 2980, 2940, 2860, 1725,
1595, 1530, 1415, 1370, 1315, 1235,
1160, 1050. TLC (Toluene: Ethyl acetate = 10:1 v/v) Rf = 0.41 (5) 6-(4-Boc-Ph)hexanoic acid 6-(4-Boc-Ph) obtained in (4) above ) Dissolve 1.94 g (6.04 mmol) of hexanoic acid methyl ester in 40 ml of methanol, add 15 ml of 1N sodium hydroxide under cooling, and then return to room temperature and react with stirring for 4 hours. Adjust the pH of the reaction solution to 1 by dropping 5% phosphoric acid aqueous solution and add 200ml of ethyl acetate.
Extract with . The organic layer is washed with distilled water and dried over anhydrous sodium sulfate. After removing the desiccant, the liquid was concentrated to dryness under reduced pressure to obtain the desired product 1.52 as a white solid.
g (yield 81.9%) is obtained.

NMR(CDCl3) δ=1.00〜2.00(b,6H),1.53(s,9H),2.15
〜2.80(m,4H),6.50〜7.03(b,1H),6.95
〜7.40(m,4H),10.03(bs,1H). IR(KBr) ν(cm-1)=3380,2980,2940,1700,1595,
1520,1510,1410,1235,1155,1050 TLC(ベンゼン:酢酸エチル:酢酸=3:2:
0.25v/v) Rf=0.63 発明の効果 本発明方法によれば収率もよく、反応時間も比
較的短かく大量合成に適した方法である。
NMR ( CDCl3 ) δ=1.00-2.00 (b, 6H), 1.53 (s, 9H), 2.15
~2.80 (m, 4H), 6.50~7.03 (b, 1H), 6.95
~7.40 (m, 4H), 10.03 (bs, 1H). IR (KBr) ν (cm -1 ) = 3380, 2980, 2940, 1700, 1595,
1520, 1510, 1410, 1235, 1155, 1050 TLC (benzene: ethyl acetate: acetic acid = 3:2:
0.25v/v) Rf=0.63 Effects of the Invention The method of the present invention has a good yield and a relatively short reaction time, making it suitable for large-scale synthesis.

Claims (1)

【特許請求の範囲】 1 一般式 〔式中R′1はグリシンあるいはセリンのアミノ
基から水素原子1個およびカルボキシル基からヒ
ドロキシル基を除いた残基(セリン残基における
ヒドロキシル基は保護されていてもよい。)を示
し、隣接するカルボニル基およびアミノ基と酸ア
ミド結合しており、R2はアミノ基の保護基を示
し、mは3から5の整数である。〕 で表される10−〔N−(ω−(4−アミノフエニル)
アシル)アミノアシル〕−1,5−ジ保護1,5,
10−トリアザデカンをグアニジノ化し、保護基を
脱離することを特徴とする。一般式 〔式中R1はグリシンあるいはセリンのアミノ
基から水素原子1個およびカルボキシル基からヒ
ドロキシル基を除いた残基を示し、mは前記に同
じである。〕 で表わされる10−〔N−(ω−(4−グアニジノフ
エニル)アシル)アミノアシル〕−1,5,10−
トリアザデカン誘導体またはその塩の製造法。
[Claims] 1. General formula [In the formula, R′ 1 represents a residue obtained by removing one hydrogen atom from the amino group of glycine or serine and the hydroxyl group from the carboxyl group (the hydroxyl group in the serine residue may be protected), and the adjacent It has an acid amide bond with a carbonyl group and an amino group, R 2 represents a protecting group for the amino group, and m is an integer from 3 to 5. ] 10-[N-(ω-(4-aminophenyl)
acyl)aminoacyl]-1,5-diprotected 1,5,
It is characterized by guanidinating 10-triazadecane and removing the protective group. general formula [In the formula, R 1 represents a residue obtained by removing one hydrogen atom from the amino group and the hydroxyl group from the carboxyl group of glycine or serine, and m is the same as above. ] 10-[N-(ω-(4-guanidinophenyl)acyl)aminoacyl]-1,5,10-
A method for producing a triazadecane derivative or a salt thereof.
JP59175117A 1984-08-24 1984-08-24 Novel method for preparation of spergualin-relating compound having phenylene group Granted JPS6153257A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP59175117A JPS6153257A (en) 1984-08-24 1984-08-24 Novel method for preparation of spergualin-relating compound having phenylene group

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59175117A JPS6153257A (en) 1984-08-24 1984-08-24 Novel method for preparation of spergualin-relating compound having phenylene group

Publications (2)

Publication Number Publication Date
JPS6153257A JPS6153257A (en) 1986-03-17
JPH0359899B2 true JPH0359899B2 (en) 1991-09-12

Family

ID=15990565

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59175117A Granted JPS6153257A (en) 1984-08-24 1984-08-24 Novel method for preparation of spergualin-relating compound having phenylene group

Country Status (1)

Country Link
JP (1) JPS6153257A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4729917A (en) * 1986-10-24 1988-03-08 Sackner Products Inc. Method and laminate for thermoforming automobile headliners and like three dimensional objects
JPH0534278Y2 (en) * 1987-01-09 1993-08-31
JPH0629125Y2 (en) * 1987-05-01 1994-08-10 東京シ−ト株式会社 Interior materials for automobiles

Also Published As

Publication number Publication date
JPS6153257A (en) 1986-03-17

Similar Documents

Publication Publication Date Title
AU2008229725B2 (en) Beta-secretase inhibitors and methods of use
KR870000357B1 (en) Process for preparing 4-substituted-2-azetidinone compounds
JPS61236770A (en) Novel amino acid derivative
FR2609716A1 (en) NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
KR19990022448A (en) Benzamide Derivatives and Uses thereof as Vasopressin Antagonists
RU2152953C1 (en) Derivatives of dipeptide p-amidinobenzylamides with n-terminal sulfonyl residues and their salts with physiologically acceptable acids
EP1157998B1 (en) Heterocyclic compounds, intermediates thereof and elastase inhibitors
JPH0159278B2 (en)
KR100300566B1 (en) Pyrimidinone derivative and method for preparation thereof
DE69512208T2 (en) AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE-A2 INHIBITORS
US6100423A (en) Amino benzenepropanoic acid compounds and derivatives thereof
US2543345A (en) Method of preparing glutamic acid amides
JPH0359899B2 (en)
US4490386A (en) Phosphate salts of 1-[2-[(1-alkoxycarbonyl-3-aralkyl)-amino]-1-oxoalkyl]octahydro-1H-indole-2-carboxylic acids, preparation of, and medical compositions thereof
CA2070983A1 (en) Cyclic renin inhibitors
CA1310443C (en) Glutamic acid derivatives, their salts, process of preparation, applications as medications, and compositions containing them
US20040009923A1 (en) Peptide analogs as irreversible interleukin-1beta protease inhibitors
US4257939A (en) Peptide derivative
JPH03505583A (en) Aminoalkylaminocarbonylaminodiol amino acid derivatives as antihypertensive agents
EP0991650B1 (en) Novel n-benzenesulphonyl-l-proline compounds, preparation method and use in therapy
US5061787A (en) Novel spergualin-related compounds and compositions
JP2002538131A (en) Method for preparing chiral β-amino ester
JPH0356462A (en) Pyroglutamic acid derivative
JPH07103101B2 (en) Pyroglutamic acid derivative
US3749706A (en) Novel dipeptide amide and process for its manufacture